roche annual report finance report part innovate healthcareinnovation spanning entire healthcare spectrum pharmaceuticals diagnostics company roche brings pioneering products services market every stage healthcare process identifying disease susceptibilities testing disease atrisk populations prevention diagnosis therapy treatment monitoring focus products deliver significant benefits patients health professionals core element business strategy one key reasons success researchintensive company longterm strategic focus roche strives deliver sustainable value stakeholderstable contents finance report roche group finance brief finance brief financial review operating results nonoperating results cash flows net cash balance sheet pensions post employment benefits roche securities financial risks international financial reporting standards roche group consolidated financial statements income statement balance sheet cash flow statement statement recognised income expense statement changes equity notes roche group consolidated financial statements report group auditors multiyear overview supplementary net income eps information roche securities roche holding ltd basel financial statements income statement balance sheet notes financial statements appropriation available earnings report statutory auditors finance report finance brief key results operating profit margin exceptional items local sales growth sales pharmaceuticals diagnostics group change sales mchf mchf chf lc sales ebitda operating profit exceptional items profit continuing businesses exceptional items net income net cash equity equity ratio core epsin chf dividend per sharein chf ebitda earnings exceptional items financial income financing costs tax depreciation amortisation including impairment corresponds operating profit exceptional items depreciation amortisation including impairment see definition core eps proposed board directors lc local currencies finance executive team erich hunziker chief financial officer hubert buck management development peter eisenring taxes insurances marco frei pension asset management andreas knierzinger treasury steve krognes corporate development karl mahler investor relations erwin schneider accounting controlling finance report finance brief sales group sales grew local currencies billion swiss francs driven primarily fast organic growth pharmaceuticals division pharmaceuticals sales increased local currencies billion swiss francs strongly outperforming global market thanks key oncology products also tamiflu bonvivaboniva lucentis pharmaceuticals sales account group sales oncology product sales grew local currencies billion swiss francs representing pharmaceuticals sales diagnostics sales increased local currencies billion swiss francs driven primarily centralized diagnostics business operating results operating profit exceptional items increased local currencies billion swiss francs based strong business growth continuing productivity improvements record profitability operating profit margin exceptional items percentage points rd expenditure increased local currencies billion swiss francs representing group sales significant investment new biotechnology manufacturing facilities treasury increase net financial income million swiss francs compared million swiss francs partial redemption lyons v convertible notes repayment bank debt reduces debt billion swiss francs financial condition increase net cash billion swiss francs billion swiss francs increase equity ratio decrease debtequity ratio aa rating moodys aa rating standard poors maintained net income increase overall net income billion swiss francs primarily strong operating performance shareholder return market capitalisation increased billion swiss francs share price price nonvoting equity security increase core eps swiss francs outpacing swiss franc sales growth percentage points increase proposed dividend swiss francs representing th consecutive year dividend growth finance report roche group financial review operating results group operating results sales operating profit exceptional items billions chf lc growth billions chf sales continuing businesses annual results show strong operating performance terms topline sales growth well profit margins mainly driven pharmaceuticals division total sales grew local currencies swiss francs us dollars billion swiss francs pharmaceuticals division contributing group sales diagnostics division representing incremental sales increase billion swiss francs achieved organic growth primarily driven strong demand groups oncology drugs herceptin avastin mabtherarituxan tarceva antiinfluenza drug tamiflu bonvivaboniva lucentis sales increase absorbing million swiss francs lower rocephin sales globally following products us patent expiry july groups operating profit exceptional items increased local currencies billion swiss francs corresponding operating profit margin grew percentage points driven increase pharmaceuticals percentage points offset decline margin diagnostics percentage points overall margin growth achieved time group continued increase investments strong development pipeline launch prelaunch activities exchange rate impact sales operating profit growth expressed swiss francs moderate swissfranc growth percentage point higher localcurrency growth average exchange rate us dollar higher euro higher japanese yen lost finance report roche group financial review group operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales operating profit exceptional items margin ebitda margin group operating results development results compared pharmaceuticals diagnostics corporate group sales increase local currencies operating profit exceptional items increase local currencies margin percentage point increase ebitda increase local currencies margin percentage point increase pharmaceuticals operating results pharmaceuticals division showed strong sales increase growth local currencies swiss francs us dollars billion swiss francs outpacing growth global market factor three operating profit exceptional items billion swiss francs representing growth local currencies consequently margin increase percentage points marketing distribution costs significantly increased local currencies billion swiss francs reflecting support recently launched onmarket products prelaunch activities global rollouts new indications rd investment pipeline continued billion swiss francs expenditure anincrease local currencies pharmaceuticals division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit exceptional items margin ebitda margin salesthe major growth drivers oncology transplantation virology franchises including tamiflu key oncology franchise significantly outpacing market renal anemia franchise declined slightly due biennial selling price cuts change reimbursement system epogin japanese market finance report roche group financial review pharmaceuticals division sales therapeutic area sales change therapeutic area mchf sales local currencies oncology inflammationautoimmunetransplantation virology metabolismbone renal anemia others total excluding tamiflu growth profitability pharmaceuticals division primarily due ten products herceptin avastin tamiflu mabtherarituxan lucentis tarceva bonvivaboniva xeloda cellcept xolair represent portfolio together grew generating billion swiss francs additional sales overall top products grew rocephin real decline due us patent expiry decline products primarily due generic erosion affecting copegus roaccutane pharmaceuticals division sales top products change sales local mchf sales currencies therapeutic area mabtherarituxan oncology iat herceptin oncology avastin oncology tamiflu virology neorecormonepogin anemia oncology cellcept iat pegasys virology xeloda oncology tarceva oncology xenical metabolismbone xolair respiratory diseases kytril oncology nutropin metabolismbone bonvivaboniva metabolismbone valcytecymevene virology lucentis ophthalmology pulmozyme respiratory diseases rocephin infectious diseases neutrogin oncology activasetnkase cardiovascular diseases total top products products total inflammationautoimmunetransplantation finance report roche group financial review mabtherarituxansales growth driven higher sales volumes particularly europe rest world excluding us japan row primarily due increased usage mabtherarituxan first line treatment indolent aggressive nonhodgkins lymphoma nhl us already high treatment rates nhl maintained price increases also contributed sales growth initial sales recorded treatment new rheumatoid arthritis indication us europerow additional driver overall growth growth potential also expected maintenance indicationtreatment immediately following firstline therapy indolent nonhodgkins lymphoma herceptin growth second highest selling product continued driven increased market share herpositive adjuvant breast cancer adj bc launch indication additional countries roche estimates end herceptin around market share adj bc five key eu markets france germany italy spain united kingdom penetration rates setting outside countries still considerably lower us growth rates appear flattened due earlier rapid adoption adjuvant treatment also contributing growth lesser extent price increase effective avastin sales continue grow strongly particularly europerow avastin launched markets worldwide initial indication firstline metastatic colorectal cancer mcrc us avastin already achieved high penetration rates following launch early continued us growth primarily driven usage avastin firstline advanced nonsmall cell lung cancer nsclc approved us food drug administration fda combination chemotherapy october also unapproved usage metastatic breast cancer mbc also growth modest increased usage firstline mcrc roche filed firstline advanced nsclc europe firstline mbc filed us eu additional filings enlarge european firstline mcrc label match broader us label planned first half filing treatment advanced renal cell carcinoma rcc europe scheduled tamiflusales continued increase mainly due government pandemic stockpiling contributed total sales also increase retail sales related pandemic preparedness seasonal sales lower last year due absence severe flu season us europe japan calendar year significant pandemic orders still due delivery neorecormonepogingrowth neorecormon driven increased usage oncology renal anemia segments offset continued pricing pressure epogin sales japan declined due biennial selling price cuts change reimbursement system overall sales anemia franchise also slightly declined cellceptsales leading treatment mycophenolic acid mpa market particularly strong us driven transplant indications increased usage treatment certain autoimmune indications currently approved continued sales growth western european countries offset sales decline latin american countries generic competition commenced pegasys market share pegasys remains global market leader treatment hepatitis c pegylated interferons sales driven increased use europerow offsetting decline us overall decline market volume japan sales declined due competition combination treatment however pegasyscopegus combination approved market january xelodathe main growth driver increased usage xeloda treatment adjuvant colon cancer mcrc filing gastric cancer submitted europe filings include combinations mcrc label including use combination avastin track first half tarcevasales continued increase us europerow accounts close overall sales months obtaining approval us sales driven approval second indication metastatic pancreatic cancer well pricing increases europe tarceva approved treatment advanced pancreatic cancer january finance report roche group financial review xolairsales growth primarily driven increased penetration asthma market lesser extent pricing increases outside us xolair marketed novartis first half genentech expects complete acquisition tanox partner development xolair bonvivaboniva vast majority sales come us boniva captured approximately market share total prescriptions bonviva granted reimbursement launched many european markets lucentis following us approval june initial sales driven high demand among existing agerelated macular degeneration amd patients previously therapies use newly diagnosed patients outside us lucentis marketed novartis rocephinsales continued decline rapidly us following patent expiry july us sales significantly lower marginal effect generic competition abating information products rd pipeline found business report sales regionsales continued grow major regions north america sales grew three times market driven products marketed genentech avastin herceptin lucentis mabtherarituxan tarceva xolair well tamiflu bonvivaboniva cellcept xeloda valcytecymevene together compensated million swiss francs decline us sales rocephin following us patent expiry july europe group continued gain market share driven continuing strong sales growth herceptin tamiflu avastin mabtherarituxan tarceva pegasys xeloda neorecormon sales japan declined due biennial governmentmandated price cuts effective april growth tamiflu sales japan government pandemic sales compensated lower seasonal flu sales sales growth herceptin neutrogin evista mainly offset decline epogin sales declined due biennial price cuts new rules introducing flatrate reimbursement epoetin products used dialysis patients reduced size anemia market whole japan pharmaceuticals division sales regions sales change region mchf sales local currencies north america europe japan regions total royalties operating incomethe increase local currencies due higher royalty income upfront income genentech increased outlicensing income roche pharmaceuticals gains product divestments significant million swiss francs compared million swiss francs cost sales increase local currencies significantly increase sales due economies scale production product mix effects addition continuing productivity improvements benefits concentrating smaller number production sites factors compensated increase royalty expenses product sales million swiss francs million swiss francs driven success mabtherarituxan tarceva xolair tamiflu gross profit share glaxosmithkline increased bonvivaboniva sales finance report roche group financial review marketing distributionthese costs increased local currencies lower growth sales spite continuing intensive support recent product launches prelaunch activities upcoming launches significant investments made us boniva lucentis europe row markets avastin tarceva worldwide pegasys mabtherarituxan new indication rheumatoid arthritis addition prelaunch costs us avastin nsclc breast cancer mircera japan strategic marketing functions strengthened sales force significantly increased reorganising specialised oncologyrenal representatives additionally japan preparation much earlier originally anticipated launches avastin tarceva also launch actemra rheumatoid arthritis furthermore past months roche established number new affiliates central eastern europe costs relating tamiflu increased properly communicate role seasonal flu pandemic planning marketing distribution costs percentage sales compared research developmentthe increase million swiss francs local currencies almost billion swiss francs reflects higher spending latestage clinical trials earlystage projects driven many additional indications particular oncology portfolio mabtherarituxan actemra rheumatoid arthritis research development costs percentage sales compared addition roche spent almost million swiss francs inlicensing pipeline compounds technologies capitalised intangible assets required ifrs total roche spent billion swiss francs internal purchased rd inlicensing alliance deals representing sales increase local currencies general administration costs grew local currencies favourable developments included lower restructuring costs particular chugai gains made disposal property overall compensated costs project harmonise sap systems across europe establish shared service centre european affiliates higher royalty expenses royalty income genentech creation new affiliates central eastern europe amortisation impairment intangible assetsthe decline local currencies primarily arose genentech intangible assets fully amortised mid impairment charge million swissfrancs recorded second half relates decision terminate development one compound alliance partner pharmaceuticals subdivisional results operating operating profit profit exceptional exceptional sales ebitda ebitda items items mchf mchf sales mchf sales roche pharmaceuticals genentech chugai pharmaceuticals division roche pharmaceuticals genentech chugai pharmaceuticals division finance report roche group financial review within pharmaceuticals division roche pharmaceuticals showed strong performance sales increase local currencies increase operating profit local currencies increase operating profit margin percentage points sales economies scale favourable product mix development lower cost ratios marketing distribution research development general administration offset impact higher royalty expenses increased gross profit share glaxosmithkline following higher bonvivaboniva sales genentech overall costs grew less significantly increased sales additionally genentech received considerably higher royalty income roche pharmaceuticals due sales success herceptin avastin mabtherarituxan tarceva consequence operating profit margin improved percentage points chugai reported slightly lower sales local currencies mainly result government price cuts increased tamiflu sales government pandemic planning fully offset impact price cuts operating profit chugai declined million swiss francs due price cuts epogin reimbursement changes mentioned previously also due marketing activities described additional information pharmaceuticals divisions subdivisional results given note consolidated financial statements andfurther information genentech chugai given notes diagnostics operating results diagnostics division increased sales billion swiss francs growing local currencies swiss francs us dollars maintaining leading market position operating profit exceptional items decreased local currencies million swiss francs although margin decline percentage points cash generation business remains well industry average ebitda lower margin primarily due investments product launches continued selling price pressure combined impairment charges intangible assets sales second half additionally royalty operating income substantially lower mainly due expiry pcrrelated patents certain onetime income despite decline operating margin remains average divisions major competitors diagnostics division results change change mchf mchf chf local currencies sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit exceptional items margin ebitda margin sales major driver sales growth centralized diagnostics immunodiagnostics applied science near patient testing also delivering solid performances continued rollout products particular rejuvenated diabetes care portfolio combined recently launched cobas modular platforms centralized diagnostics helped strengthen roches position market segments led increase growth second half finance report roche group financial review diagnostics division sales business area sales change business area mchf sales local currencies diabetes care centralized diagnostics immunochemistry molecular diagnostics near patient testing applied science total diabetes care diabetes care maintained number one position blood glucose monitoring sales billion swiss francs increase local currencies following rebound growth second half year sales accuchek blood glucose monitoring meters strips lancets increased local currencies billion swiss francs insulin delivery sales grew million swiss francs global rollout new portfolio completed mid launch accuchek compact plus us canada accuchek aviva japan new accuchek aviva meter experienced rapid uptake markets launched reversed sales decline maturation accuchek advantage line accuchek compact plus continues expand new integrated market segment commands share remains meter market integrating measuring test strip lancet one device october us food drug administration fda lifted import alert barring sale accuchek insulin pumps united states allowing roche immediately reenter worlds largest infusion systems market centralized diagnosticssales increased local currencies billion swiss francs increasing roches lead highly competitive segment immunochemistry sales grew significantly market rate sixth successive year growth billion swiss francs significant immunochemistry instrument placements combined increasing demand cardiac test elecsys probnp resulting strong reagent sales sales clinical chemistry increased volume however ongoing price pressure segment meant sales declined flat market launch mid cobas analyser series labs medium workloads first series modular platform designed integrate improve efficiency clinical chemistry immunochemistry testing different sized laboratories strengthen product offering important market segment molecular diagnostics molecular diagnostics remained clear market leader sales billion swissfrancs growth local currencies sales virology grew local currencies million swiss francs flat market supported new automated platforms helped combat pricing pressure highly competitive segment blood screening showed evidence slowing growth sales million swiss francs decrease local currencies increase number centres coming online offset price reduction japan earlier year june roche began rolling across europe new fully automated cobas modular blood screening system cobas taqscreen mpx multiplex test simultaneously detects hiv hcv hbv donated blood plasma roche track submit filings fda first half tests detect genotype low highrisk types human papillomavirus hpv near patient testing sales rose million swiss francs helped improved marketing business areas broad portfolio continued move towards decentralised testing coagulation sales increased local currencies million swiss francs due growing trend towards patient selfmonitoring new coagulation monitoring systems coaguchek xs patient selfmonitoring coaguchek xs plus forhealthcare professionals commenced european rollout january october respectively full us launch coaguchek xs professional use planned first quarter applied sciencein highly fragmented competitive life science market applied science grew million swiss francs twice market rate major contributors sales genome sequencer system dna sequencing lightcycler system highthroughput realtime pcr andthe industrial business reagents industrial processes finance report roche group financial review sales regions sales continued grow ahead local market regions exception northamerica north america returned positive growth second half helped immunochemistry rebound diabetes care sales growth japan particularly strong given acrosstheboard price cut april diagnostics division sales regions sales change region mchf sales local currencies north america emea japan regions total europe middle east africa excluding iberia royalties operating income million swiss francs royalty operating income local currencies million swiss francs lower comparative period included substantial oneoff income outlicensing agreements royalty income lower due expiry march foundational pcr patents countries outside us us patents expired march cost sales overall increase local currencies considerably higher sales growth result business area mix product mix impacts higher depreciation resulting significantly increased leasedout instruments base royalty expenses million swiss francs higher inlocal currencies primarily due centralized diagnostics cost sales percentage sales increased marketing distribution costs remained stable level increased overall investment offset significant launch expenses number new diabetes care products comparative numbers addition sample consumption inventory writeoffs lower global functions across division business areas streamlined marketing distribution percentage sales declined research developmentcosts decreased slightly local currencies decline reflects changes timing projects lower expenses thirdparty collaborations percentage sales research development costs declined general administrationthese costs increased local currencies mainly due increased accruals prior year royalties following ongoing discussions various contract partners addition restructuring expenses million swiss francs amortisation impairment intangible assetsthe increase due impairment charges million swiss francs recorded second half following updating divisions business plans technology assessments charges mainly relate intangible assets recorded disetronic acquisition corporate operating costs general administration costs increased million swiss francs million swiss francs explained inclusion results gain million swiss francs settlement pension plans chugai excluding corporate operating costs declined finance report roche group financial review exceptional operating items major legal casesthere income statement impacts developments major legal cases additional information major legal cases given note consolidated financial statements total operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf mchf mchf mchf mchf operating profit exceptional items major legal cases operating profit operating profit increase million swiss francs local currencies reflects strong business expansion continued improvement groups operating performance inclusion exceptional items major legal cases comparative results nonoperating results groups treasury operations pension management delivered positive net financial income net income financial assets foreign exchange management exceeding financing costs million swiss francs groups effective tax rate increased percentage points mainly due increase effective tax rate genentech profit continuing businesses net income increased due combination positive developments operating financial lines absence major legal case expenses compensated increase effective tax rate nonoperating results change mchf mchf chf operating profit associated companies financial income financing costs profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests net financial income millions chf financing costs financial income net financial income finance report roche group financial review financial income financial income showed strong increase compared net income equity securities million swiss francs compared million swiss francs driven strongly performing equity markets disposal equity investments interest income income debt securities almost doubled million swiss francs due higher holdings increases interest rates expected returns pension plan assets million swiss francs line net foreign exchange losses million swiss francs compared losses million swiss francs full analysis financial income given note consolidated financial statements financing costsfinancing costs million swiss francs declined compared interest expenses increased result billion us dollar senior notes issued genentech mid partly compensated lower interest expenses resulting partial conversion lyons v notes bank debt redemption debt instruments fixed increasing interest rates major impact financing costs interest costs defined benefit plans million swiss francs slightly lower full analysis financing costs given note consolidated financial statements income taxesthe groups effective tax rate compared rate main influence increase effective tax rate genentech interim results accounting equity compensation plans adversely affected effective tax rate genentech development genentech share price meant small accounting tax benefit recorded expensing equity compensation plans addition tax charge genentech includes certain tax credits excluding genentech chugai underlying effective tax rate slightly lower rate analysis effective tax rate given note consolidated financial statements profit continuing businesses billions chf net income billions chf profit continuing businessesthe increase compared due positive developments operating financial lines excluding exceptional item major legal cases profit continuing businesses increased billion swiss francs discontinued businessesthere significant results discontinued operations showing small release provisions longer required comparative results include operating results remaining consumer health otc business transferred bayer information discontinued businesses given note consolidated financial statements net income group net income increased billion swiss francs return sales margin net income attributable roche shareholders higher comparative period share net income attributable minorities increased million swiss francs due continually improving profit contribution genentech within million swiss francs attributable genentech minority interests million swiss francs chugai minority interests diluted eps chf chf change group core increase diluted eps due higher net income core eps excludes exceptional items also amortisation impairment intangible assets increased swiss francs swiss francs shows underlying improvements groups operating financial results supplementary net income eps information given includes calculations profit continuing businesses exceptional items core eps reconciles groups published ifrs results finance report roche group financial review cash flows net cash cash flows operating activities net cash income taxes billions chf billions chf condensed cash flow statement mchf mchf cash generated operations increase decrease working capital costs major legal cases paid operating cash flows operating activities income taxes income taxes paid activities operating activities investing activities financing activities net effect currency translation cash increase decrease cash full consolidated cash flow statement given consolidated financial statements operating cash flowsthe groups business operations continued show strong cash generation billion swiss francs driven continued growth ebitda development business led increase working capital mainly inventories trade receivables particular increases genentech growth business central eastern europe income tax payments increased due payments made genentech chugai total operating cash flows taxes increased billion swissfrancs investing cash flows largest investing cash flows expenditure property plant equipment billion swiss francs particularly biotechnology manufacturing facilities net reinvestment cash marketable securities billion swiss francs comparative cash flows include receipt bayer billion swiss francs proceeds divestment consumer health otc business billion swiss francs used genentech purchase oceanside biologics manufacturing facility financing cash flows significant financing cash flows relate dividend payments redemption debt instruments dividends paid roche billion swiss francs billion swiss francs cash used redemption debt instruments billion swiss francs used purchase equity instruments cover partial conversion lyons v notes compared billion swiss francs used sumo bonds following partial conversion lyons v notes group reduced equity instruments holdings realising cash inflow billion swiss francs genentech issued billion us dollars senior notes resulting cash inflow equivalent billion swiss francs genentech received billion swiss francs stock option exercises billion swiss francs repurchased shares billion swiss francs billion swiss francs finance report roche group financial review net cash december december mchf mchf change cash cash equivalents marketable securities longterm debt shortterm debt net cash net cash increased billion swiss francs main drivers strong cash inflow operating activities billion swiss francs expenditures property plant equipment roche dividend payment increase shortterm debt due reclassification lyons v notes us dollar european medium term notes longterm shortterm debt balance sheet balance sheet billions chf liabilities assets net assets equity condensed balance sheet december december mchf mchf change property plant equipment goodwill intangible assets noncurrent assets cash marketable securities current assets total assets debt current noncurrent noncurrent liabilities current liabilities total liabilities total net assets capital reserves attributable roche shareholders equity attributable minority interests total equity full consolidated balance sheet given consolidated financial statements noncurrent assets decrease us dollar swiss franc december december decreased longterm assets swiss franc terms since many groups production facilities intangible assets denominated us dollars offset capital expenditure billion swiss francs finance report roche group financial review current assetsinventories accounts receivable higher local currencies following growth business total balance cash marketable securities increased billion swiss francs result groups strong cash generation debt partial conversion lyons v notes repayment bank loans reduced debt billion swiss francs remaining billion swiss francs carrying value lyons v notes classified shortterm debt due groups option redeem notes july onwards additionally movement us dollar exchange rate decreased swiss franc carrying value groups us dollardenominated debt instruments noncurrent current liabilitiesthere significant movements overall balance local currencies movement due currency translation transfers current non current liabilities total net assetsequity significant movements net income billion swiss francs roche dividend payments billion swiss francs currency translation losses billion swiss francs currency translation losses mainly arose decrease us dollar relative swiss franc particularly affects balance sheet values assets liabilities concentrations us property plant equipment goodwill intangible assets debt strong financial condition group remains solidly financed equity including minority interests representing total assets total assets financed longterm pensions postemployment benefits postemployment benefit plans classified defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans million swiss francs million swiss francs increase arising mainly genentech plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising funding asset management groups various defined benefit plans overseen corporate level plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources funding status defined benefit pension postemployment benefit plans mchf mchf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation funding status overall groups defined benefit plans continue adequately funded main movements arising better expected returns plan assets currency translation effects plans denominated us dollars euros funding status increased increase discount rates used valuations eurozone plans reduced defined benefit obligations slightly finance report roche group financial review expenses recorded income statement pension expenses relating groups defined benefit plans million swiss francs double expenses million swiss francs mainly due onetime settlement gain million swiss francs arose chugai returned part employees pension fund japanese government excluding pension costs increased mainly due changes discount rates adopted end revised actuarial assumptions included actuarial valuations end expected lead increases partly arise increased life expectancy full details groups pensions postemployment benefits given note consolidated financial statements roche securities price development roche securities outperformed peer group healthcare companiesbut rose slightly less swiss market share price market capitalisation december change share price chf nonvoting equity security genussscheinprice chf market capitalisation chf billions roche ranked number among peers listed terms total shareholder return tsr ie share price growth plus dividends measured swiss francs yearend return roche share roche nonvoting equity security combined performance share nonvoting equity security compared weighted average return roche peer group actual exchange rates total shareholder return development price tsr roche share roche gs peer group actual exchange rates dec march june sept dec roche share roche gs peer group dividend board directors proposing increase dividend swiss francs per share nonvoting equity security swiss francs approval annual general meeting th consecutive increase dividend dividend proposal approved shareholders dividend payments shares nonvoting equity securities issue amount billion swiss francs billion swiss francs resulting payout ratio based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given finance report peer group abbott laboratories amgen astrazeneca bayer becton dickinson biogen idec bristolmyers squibb elililly glaxosmithkline johnson johnson merck novartis pfizer sanofiaventis scheringplough takeda wyeth finance report roche group financial review information per share nonvoting equity security information per share nonvoting equity security chf chf change basic eps diluted eps core eps equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements finance report financial risks valueatrisk earningsatrisk analysis tools valueatrisk var calculations used indicate ranges within value respective assets liabilities may fluctuate certain probability certain time period holding period var measure statistical measure implicitly assuming value changes recent past indicative value changes future market shocks included calculation extent occurred observation period group uses statistically relevant observation periods applies holding periods reflect time period required change respective risk exposure deemed appropriate longer holding periods probability higher value changes increases var measure earningsatrisk ear equivalent var methodology rather potential value changes indicates potential changes profits losses certain probability certain time period constraints limitations apply methodology var ear figures interest rate risks measured using historical simulation approach historical scenario representing price rate changes individual instruments specific day period past years financial instruments fully revalued using valuation models total change value earnings determined var ear calculations based confidence level holding period trading days group predict future market movements var ear figures given represent actual losses expected might incurred financial assets liabilities possible worst loss period stated consider effect favourable changes market rates foreign exchange risk groups exposure movements foreign currencies affecting net income financial position expressed swiss francs summarised following key figures comments growth continuing businesses change local currencies change chf sales operating profit exceptional items finance report roche group financial review exchange rates swiss franc december average december average usd eur gbp jpy average us dollar euro slightly strengthened swiss franc compensating weaker yen consequently almost difference sales growth operating profit growth expressed swiss francs local currencies absolute terms sensitivity group sales continuing businesses movement us dollar swiss franc swiss francs approximately million swiss francs corresponding sensitivities euro yen approximately million swiss francs million swiss francs respectively group pursued strategy continuously lock favourable developments foreign exchange rates entering derivative contracts due increased hedging activities associated strong sales growth group foreign exchange transaction var increased compared low exposure year end absolute terms still remained low level foreign exchange risks december december mchf mchf change var monetary positions interest rate risk interest rate risk arises movements interest rates could adverse effects groups net income financial position changes interest rates cause variations interest income expenses interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments appropriate group uses financial derivatives swaps manage interest rate risk group unwound fair value hedges fixedrate capital market debt leading increased interest rate var effect partly compensated debt reduction billion swiss francs due redemption outstanding bank debt partial conversion lyons v convertible notes effect higher liquid funds interest rate var small instruments short duration comparatively small risks repricing refinancing contained reasonable levels however earningsatrisk ear increased mainly result liquid funds held short interest rate commitments generally higher interest rate levels allow room downward changes interest rates interest rate risks december december mchf mchf change var instruments sensitive interest rates ear instruments sensitive interest rates finance report roche group financial review market risk financial assets liabilities changes market value financial assets liabilities affect net income financial position group market risk arises movements stock prices interest rates foreign exchange rates groups financial assets mostly held highly liquid bonds money market instruments equity allocation groups portfolio cash marketable securities billion swiss francs total cash marketable securities figure remained stable compared billion swiss francs total cash marketable securities international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since international accounting standards board iasb published number new revised standards interpretations first became effective group implemented january significant changes relate roche group financial statements arise ias revised employee benefits particular respect defined benefit pension postemployment benefits changes implemented effective january comparative results havebeen restated changes previously published defined benefit plans actuarial gains losses actuarial gains losses recognised immediately recorded directly equity previously actuarial gains losses certain threshold recognised threshold recognised progressively result change groups consolidated balance sheet accurately represents funding status various plans defined benefit plans expected return plan assets interest cost group reports expected return plan assets interest costs defined benefit plans part financial income financing costs respectively previously reported part divisional operating results change presentation aligns reporting groups results closely internal management organisation structure full details changes given note consolidated financial statements supplementary presentation materials investor update held june available investor relations section groups website wwwrochecom finance report roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit exceptional items major legal cases operating profit associated companies financial income financing costs profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests continuing earnings per share nonvoting equity security businesses group basic chf diluted chf finance report roche group roche group consolidated financial statements consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration amortisation impairment intangible assets operating profit exceptional items major legal cases operating profit associated companies financial income financing costs profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests continuing earnings per share nonvoting equity security businesses group basic chf diluted chf disclosed note income statement restated following changes ifrs adopted effective january reconciliation previously published income statement provided note finance report roche group roche group consolidated financial statements consolidated balance sheet millions chf december december noncurrent assets property plant equipment goodwill intangible assets associated companies financial longterm assets longterm assets deferred income tax assets postemployment benefit assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred income tax liabilities postemployment benefit liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable minority interests total equity disclosed note balance sheet restated following changes ifrs adopted effective january reconciliation previously published balance sheet provided note finance report roche group roche group consolidated financial statements consolidated cash flow statement millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital major legal cases payments made defined benefit postemployment plans utilisation restructuring provisions utilisation provisions operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets disposal products business combinations divestments discontinued businesses divestments subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue longterm debt instruments repayment redemption longterm debt instruments increase decrease longterm debt transactions equity instruments increase decrease shortterm borrowings interest dividends paid exercises equitysettled equity compensation plans genentech share repurchases financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december finance report roche group roche group consolidated financial statements consolidated statement recognised income expense millions chf year ended december availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations defined benefit postemployment plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity net income recognised directly equity net income recognised income statement total recognised income expense attributable roche shareholders minority interests total effect changes accounting policy attributable roche shareholders minority interests total disclosed note statement recognised income expense restated following changes ifrs adopted effective january reconciliation previously published statement recognised income expense provided note finance report roche group roche group consolidated financial statements consolidated statement changes equity millions chf roche minority shareholders interests total year ended december january previously reported changes accounting policy january restated net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech share repurchases convertible debt instruments changes minority interests december year ended december january net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech share repurchases convertible debt instruments changes minority interests december finance report notes roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved issue board directors february subject approval annual general meeting shareholders march preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure ofcontingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change changes accounting policies arise application new revised standards interpretations applied retrospectively unless otherwise specified transitional requirements particular standard interpretation retrospective application requires results comparative period opening balances period restated new accounting policy always applied cases transitional requirements particular standard interpretation specify changes applied prospectively prospective application requires new accounting policy applied results current period comparative period restated addition comparatives reclassified extended previously reported results take account presentational changes consolidation policy financial statements consolidated financial statements roche holding ltd company registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enterprise obtain benefits fromits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights potential voting rights companys share capital special purpose entities consolidated substance relationship special purpose entity controlled thegroup companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full investments associated companies accounted equity method companies group exercises power exercise significant influence control normally evidenced group owns voting rights potential voting rights company balances transactions associated companies result unrealised income eliminated extent groups interest associated company interests joint ventures reported using linebyline proportionate consolidation method segment reporting groups primary format segment reporting business segments secondary format geographical segments risks returns groups operations primarily determined different products group produces rather geographical location groups operations reflected groups management organisational structure internal financial reporting systems finance report roche group notes roche group consolidated financial statements determination groups business geographical segments based organisation units information reported groups management group two divisions pharmaceuticals diagnostics within pharmaceuticals division three subdivisions roche pharmaceuticals genentech chugai three subdivisions separate management reporting structures within pharmaceuticals division considered separately reportable business segments vitamins fine chemicals business consumer health otc business previously separately reportable business segments divested presented discontinued businesses certain headquarter activities reported corporate consist corporate headquarters including corporate executive committee corporate communications corporate human resources corporate finance including treasury taxes pension fund management corporate legal corporate safety environmental services groups geographical segments determined geographical location similarity economic environments transfer prices business segments set arms length basis divisional assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories segment liabilities consist liabilities provisions reasonably attributed reported business segments nonsegment assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities principally cash marketable securities investments debt capital expenditure comprises additions goodwill intangible assets property plant equipment including arising business combinations foreign currency translation group companies use local currency functional currency certain group companies use currencies namely us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity deferred equity upon consolidation assets liabilities group companies using functional currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity disposal foreign entity identified cumulative currency translation differences within equity relating foreign entity recognised income part gain loss divestment revenues cost sales sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude sales value added taxes revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid united states similar rebates countries also deducted sales recorded deduction accounts receivable accrued liabilities provisions estimates based analyses existing contractual legislativelymandated obligations historical trends groups experience revenues recorded earned services performed necessary single transactions split separately identifiable components reflect substance transaction conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole cost sales includes corresponding direct production costs related production overheads goods sold services rendered startup costs validation achievement normal production capacity expensed incurred finance report roche group notes roche group consolidated financial statements royalty income expenses royalty income expenses recognised accrual basis royalty expenses directly linked goods sold included cost sales royalty expenses included general administration research development addition internal research development activities group also party inlicensing similar arrangements alliance partners furthermore group may acquire inprocess research development assets either business combinations purchases specific assets internal research costs charged income incurred internal development costs capitalised intangible assets identifiable asset completed generate probable future economic benefits cost asset measured reliably group currently internal development costs qualify capitalisation intangible assets internal development costs charged income incurred since criteria recognition asset met inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases capitalised intangible assets described available use intangible assets amortised straightline basis period expected benefit reviewed impairment balance sheet date licensing milestone upfront receipts payments certain group companies receive third parties upfront milestone similar payments relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence feesfor subsequent deliverables initially reported deferred income recognised revenue income earned period development collaboration manufacturing obligation payments made group companies third parties associated companies items capitalised intangible assets receipts payments consolidated subsidiaries genentech chugai roche group subsidiaries eliminated consolidation taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future deferred income tax assets liabilities recognised temporary differences tax bases assets liabilities carrying amounts financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied sametaxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates finance report roche group notes roche group consolidated financial statements discontinued businesses noncurrent assets held sale discontinued business component groups business represents separate major line business geographical area operations subsidiary acquired exclusively view resale reclassification discontinued business occurs upon disposal operation meets criteria classified held sale earlier disposal group group assets disposed group single transaction together withthe liabilities directly associated assets transferred transaction assets liabilities disposal group reclassified held sale value recovered principally sale rather continuing use disposal group must available sale current condition sale must highly probable immediately classification held sale measurement assets liabilities disposal group updated accordance applicable accounting policies initial reclassification held sale disposal groups recognised lower carrying amount fair value less costs sell impairment losses initial classification held sale included income statement employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned liabilities longterm employee benefits discounted take account time value money material pensions postemployment benefits employees covered defined benefit defined contribution postemployment plans sponsored group companies groups contributions defined contribution plans charged appropriate income statement heading within operating results year relate accounting reporting defined benefit plans based recent actuarial valuations defined benefit obligations service costs calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return plan assets discount rates based market yields highquality corporate bonds country concerned past service costs allocated average period benefits become vested current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate business segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses consist differences assumptions actual experiences effects changes actuarial assumptions recorded directly equity pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly equity equity compensation plans certain employees group participate equity compensation plans including separate plans genentech chugai fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded subsequent cash flows exercises vested awards recorded increase equity cashsettled plans liability recorded measured fair value balance sheet date movements fair value recorded appropriate income statement heading within operating results subsequent cash flows exercises vested awards recorded reduction liability finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate items estimated useful life assets regularly reviewed necessary future depreciation charge accelerated repairs maintenance costs expensed incurred borrowing costs capitalised leases group lessee leases property plant equipment group substantially risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt assets acquired finance leases depreciated accordance groups policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method leases substantially risks rewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease group lessor assets subject finance leases reported receivables amount equal net investment lease assets subject operating leases reported within property plant equipment lease income finance leases recognised term lease based effective interest rate method lease income operating leases recognised lease term straightline basis business combinations goodwill business combinations accounted using purchase method accounting cost acquisition consideration given exchange control identifiable assets liabilities contingent liabilities acquired company consideration includes cash paid plus fair value date exchange assets given liabilities incurred assumed equity instruments issued group cost acquisition also includes directly attributable costs acquired net assets identifiable assets liabilities contingent liabilities initially recognised fair value group acquire ownership acquired company minority interest recorded minoritys proportion fair value acquired net assets goodwill recorded surplus cost acquisition groups interest fair value acquired net assets goodwill fair value adjustments recorded assets liabilities acquired company recorded functional currency company goodwill amortised assessed possible impairment balance sheet date additionally tested annually impairment goodwill may also arise upon investments associated companies surplus cost investment groups share fair value net identifiable assets goodwill recorded within investments associated companies finance report roche group notes roche group consolidated financial statements intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination fair value allocated acquisition accounting intangible assets amortised useful lives straightline basis beginning point available use estimated useful life lower legal duration economic useful life estimated useful life intangible assets regularly reviewed amortisation impairment intangible assets presented separately income statement due materiality amounts order fairly present groups results impairment property plant equipment intangible assets evidence asset may impaired recoverable amount asset calculated impairment assessment carried addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs sell value use less carrying amount carrying amount reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy impairment goodwill impairment assessment goodwill carried annually goodwill allocated cashgenerating units described note recoverable amount cashgenerating unit higher fair value less costs sell value use less carrying amount impairment carrying amount recorded methodology used impairment testing described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities borrowing costs included cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded difference carrying amount recoverable amount objective evidence group able collect amounts due trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience longterm accounts receivable discounted take account time value money material provisions sales returns sales chargebacks reported provisions accrued liabilities respectively cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash readily convertible known amounts cash subject insignificant risk changes value maturity three months less date acquisition definition also used cash flow statement finance report roche group notes roche group consolidated financial statements provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise taking account foreign currency effects arising translation functional currency swiss francs time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices use established estimation techniques option pricing models estimated discounted values cash flows fair values financial assets liabilities balance sheet date approximately line reported carrying values unless specifically mentioned notes consolidated financial statements financial assets financial assets principally investments including marketable securities classified either fairvalue throughprofitorloss availableforsale heldtomaturity loans receivables fairvaluethrough profitorloss financial assets either classified heldfortrading designated upon initial recognition heldfortrading financial assets acquired principally generate profit shortterm fluctuations price financial assets designated fairvaluethroughprofitorloss results relevant information eliminating measurement recognition inconsistency heldtomaturity financial assets securities fixed maturity group intent ability hold maturity loans receivables loans longterm financial assets created group acquired issuer primary market nonderivative financial assets fixed determinable payments quoted active market financial assets considered availableforsale financial assets initially recorded fair value including transaction costs except assets designated fairvaluethroughprofitorloss exclude transaction costs purchases sales recognised settlement date fairvaluethroughprofitorloss financial assets subsequently carried fair value changes fair value recorded financial income period arise heldtomaturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded equity except interest calculated using effective interest rate method foreign exchange components availableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised equity included financial income current period loans receivables subsequently carried amortised cost financial assets assessed possible impairment balance sheet date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale financial assets market value original cost net previous impairment considered impaired available forsale financial assets market value original cost net previous impairment sustained sixmonth period considered impaired decreases market price less original cost net previous impairment also less sustained sixmonth period considered objective evidence impairment movements fair value recorded equity objective evidence impairment asset sold otherwise disposed financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried equity difference original cost net previous impairment fair value finance report roche group notes roche group consolidated financial statements financial assets derecognised contractual rights cash flows assets expire group sells otherwise disposes contractual rights cash flows including situations group retains contractual rights assumes contractual obligation pay cash flows third party derivatives derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments see changes fair value recorded financial income period arise embedded derivatives recognised separately closely related host contract host contract carried amortised cost hedging purposes hedge accounting hedging relationships may three types fair value hedges hedges particular risks may change fair value recognised asset liability cash flow hedges hedges particular risks may change amount timing future cash flows hedges net investment foreign entity hedges particular risks may change carrying value net assets foreign entity qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk anychanges fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion change infairvalue effective hedge included equity remaining ineffective portion reported financial income hedging relationship hedge firm commitment highly probable forecasted transaction results recognition nonfinancial asset liability cumulative changes fair value hedging instrument recorded equity included initial carrying value asset liability date recognition qualifying cash flow hedges cumulative changes fair value hedging instrument recorded equity included financial income forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion recorded financial income hedging instrument derivative equity cases entity disposed cumulative changes fair value hedging instrument recorded equity reclassified income debt instruments debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost using effective interest method discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method certain debt instruments may designated fairvaluethroughprofitorloss results relevant information eliminates significantly reduces measurement recognition inconsistencies debt instruments reported fair value based quoted prices active market movements fair value reported within financial income debt instruments designated fairvaluethroughprofitorloss disclosed note finance report roche group notes roche group consolidated financial statements bifurcation carried upon issue convertible debt instruments initial carrying value liability element calculated using market interest rate equivalent nonconvertible instrument remainder net proceeds allocated equity conversion option reported equity deferred income tax liabilities liability element subsequently reported amortised cost fairvaluethrough profitandloss designated equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet obligations may arise respect certain groups debt instruments management judgements made applying accounting policies application groups accounting policies may require management make judgements apart involving estimates significant effect amounts recognised consolidated financial statements management judgement particularly required assessing substance transactions complicated structure legal form include limited following areas revenue recognition nature groups business many sales transactions simple structure sales agreements may consist multiple components occurring different times group also party various outlicensing agreements involve upfront milestone payments may occur several years agreements may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement leases group party leasing arrangements lessee lessor treatment leasing transactions financial statements mainly determined whether lease considered operating lease finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred key assumptions sources estimation uncertainty preparation consolidated financial statements conformity ifrs requires management make estimates assumptions affect application policies reported amounts assets liabilities income expenses related disclosures estimates underlying assumptions based historical experience various factors believed reasonable circumstances results form basis making judgements carrying values assets liabilities readily apparent sources actual results may differ estimates estimates underlying assumptions reviewed ongoing basis changes accounting estimates may necessary changes circumstances estimate based result new information experience changes recognised period estimate revised key assumptions future key sources estimation uncertainty significant risk causing material adjustment carrying value assets liabilities within next twelve months described finance report roche group notes roche group consolidated financial statements sales allowances group accruals provisions expected sales returns chargebacks rebates including medicaid united states similar rebates countries december total million swiss francs estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience management believes total accruals provisions items adequate based upon currently available information deductions based management estimates may subject change better information becomes available changes arise could impact accruals provisions recognised balance sheet future periods consequently level sales recognised income statement future periods property plant equipment intangible assets including goodwill group property plant equipment carrying value million swiss francs disclosed note goodwill carrying value million swiss francs see note intangible assets carrying value million swiss francs see note assets reviewed annually impairment described assess whether impairment exists estimates made future cash flows expected result use asset eventual disposal actual outcomes could vary significantly estimates discounted future cash flows factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment pensions postemployment benefits many groups employees participate post employment defined benefit plans calculations recognised assets liabilities plans based upon statistical actuarial calculations particular present value defined benefit obligation impacted assumptions discount rates used arrive present value future pension liabilities assumptions future increases salaries benefits furthermore groups independent actuaries use statistically based assumptions covering areas future withdrawals participants plan estimates life expectancy december present value groups defined benefit obligation million swiss francs funded plans million swiss francs unfunded plans see note actuarial assumptions used may differ materially actual results due changes market economic conditions higher lower withdrawal rates longer shorter life spans participants changes factors assessed differences could impact assets liabilities recognised balance sheet future periods legal provisions group companies party various legal proceedings significant matters described notes legal provisions december total million swiss francs disclosed note additional claims could made might covered existing provisions insurance assurance increase scope matters future lawsuits claims proceedings investigations material changes arise could impact provisions recognised balance sheet future periods environmental provisions group provisions environmental remediation costs december total million swiss francs disclosed note material components environmental provisions consist costs fully clean refurbish contaminated sites treat contain contamination certain sites future remediation expenses affected number uncertainties include limited detection previously unknown contaminated sites method extent remediation percentage waste material attributable group remediation sites relative attributable parties financial capabilities potentially responsible parties management believes total provisions environmental matters adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued effect resolution environmental matters results operations predicted due uncertainty concerning amount timing future expenditures changes arise could impact provisions recognised inthe balance sheet future periods finance report roche group notes roche group consolidated financial statements income taxes december net liability current income taxes million swiss francs net liability deferred income taxes million swiss francs disclosed note significant estimates required determine current deferred assets liabilities income taxes estimates based interpretations existing tax laws regulations management believes estimates reasonable recognised liabilities income taxrelated uncertainties adequate various internal external factors may favourable unfavourable effects income tax assets liabilities factors include limited changes tax laws regulations andor rates changing interpretations existing tax laws regulations future levels research development spending changes overall levels pretax earnings changes arise could impact assets liabilities recognised balance sheet future periods changes accounting policies group adopted certain new revised international financial reporting standards interpretations effective january description changes material group effect consolidated financial statements given ias revised employee benefits amongst matters revised standard allows actuarial gains losses defined benefit plans recorded directly equity case adjustments arising limits recognition assets defined benefit plans also recorded directly equity revised standard requires retrospective application addition group reports expected return plan assetsand interest costs defined benefit plans part financial income financing costs respectively corresponding postemployment benefit assets liabilities included nonsegment assets liabilities segment reporting change presentation aligns reporting groups results closely internal management organisation structure information groups pension postemployment benefits given note presentation income statement income statement year ended december restated following changes ifrs adopted effective january addition group made certain presentational changes improve comparability results healthcare companies allow readers make accurate assessment sustainable earnings capacity group changes applied retrospectively listed support costs leased diagnostics instruments reported part cost sales instead marketing distribution million swiss francs million swiss francs restated income statement year ended december millions chf originally ias group published revised restated sales operating items operating profit financial nonoperating items profit taxes income taxes profit continuing businesses profit discontinued businesses net income attributable roche shareholders minority interests earnings per share nonvoting equity security basic group chf diluted group chf finance report roche group notes roche group consolidated financial statements presentation balance sheet balance sheet december restated result changes ifrs adopted effective january result implementation ias revised postemployment benefit assets million swiss francs lower deferred income tax assets million swiss francs higher postemployment benefit liabilities million swiss francs higher deferred income tax liabilities million swiss francs lower restated balance sheet december millions chf originally ias group published revised restated noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities total net assets minority interests equity presentation recognised income expense changes equity new revised standards adopted effective january result significant changes format content changes equity ias revised requires retrospective implementation accordingly opening equity statement recognised income expense restated restated equity january millions chf originally ias group published revised restated share capital equity instruments retained earnings fair value reserve hedging reserve translation reserve equity attributable roche shareholders minority interests total equity restated recognised income expense year ended december millions chf originally ias group published revised restated net income recognised directly equity net income recognised income statement total recognised net income attributable roche shareholders minority interests total finance report roche group notes roche group consolidated financial statements future changes ifrs group currently assessing potential impacts new revised standards effective january group expect new revised standards interpretations significant effect groups results financial position although expand financial statement disclosure certain areas notably ifrs financial instruments disclosures group implement group also process evaluating ifrs operating segments effective january financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties groups subsidiaries genentech chugai treasury operations operational independence whilst working within financial risk management framework consistent rest group information financial risks available annual reports genentech chugai financial risk management within group governed policies guidelines approved senior management policies guidelines cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policies guidelines also cover areas cash management investment excess funds raising short longterm debt compliance policies guidelines managed segregated functions within group objective financial risk management contain deemed appropriate exposures various types financial risks mentioned order limit negative impact groups results financial position group actively measures monitors manages financial risk exposures various functions pursuant segregationofduties principles accordance financial risk policies group manages market risk exposures use financial instruments derivatives deemed appropriate groups policy practice enter derivative transactions trading speculative purposes purposes unrelated underlying business foreign exchange risk group operates across world exposed movements foreign currencies affecting net income financial position expressed swiss francs group actively monitors currency exposures appropriate enters transactions aim preserving value assets commitments anticipated transactions group uses forward contracts foreign exchange options crosscurrency swaps hedge certain committed anticipated foreign exchange flows financing transactions transaction exposure arises amount local currency paid received transactions denominated foreign currencies may vary due changes exchange rates similarly transaction exposure arises net balances monetary assets held foreign currencies many group companies revenues operating expenses primarily local currency local level group companies manage exposure necessary means financial instruments options forward contracts addition group treasury monitors total worldwide exposure monthly basis translation exposure arises consolidation foreign currency denominated financial statements groups foreign subsidiaries effect groups consolidated equity shown currency translation movement group partially hedges net investments foreign currencies taking foreign currency loans issuing foreign currency denominated debt instruments major translation exposures monitored regularly finance report roche group notes roche group consolidated financial statements significant part groups cash outflows research development production administration denominated swiss francs much smaller proportion groups cash inflows swiss franc denominated result increase value swiss franc relative currencies adverse impact consolidated net income similarly relative decrease value swiss franc favourable effect results reported swiss francs interest rate risk interest rate risk arises movements interest rates could effects groups net income financial position changes interest rates may cause variations interest income expenses resulting interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments described following section market risk financial assets interest rates groups major debt instruments fixed described note group uses interest rate derivatives manage interest rate risk market risk financial assets changes market value certain financial assets derivative instruments affect net income financial position group financial longterm assets held strategic purposes marketable securities held fund management purposes risk loss value managed reviews prior investing continuous monitoring performance investments changes risk profile investments equities bonds debentures fixed income instruments entered basis guidelines regard liquidity credit rating credit risk credit risk arises possibility counterparty transaction may unable unwilling meet obligations causing financial loss group trade receivables subject policy active risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures except noted significant concentrations within trade receivables counterparty credit risk due groups large number customers wide geographical spread credit exposures critical countries group obtained credit insurance country risk exposures continuously monitored exposure financial assets credit risk controlled settinga policy limiting credit exposure highquality counterparties regular reviews credit ratings setting defined limits counterparty appropriate reduce exposure netting agreements isda international swaps derivatives association master agreement signed respective counterparties maximum exposure credit risk resulting financial activities without considering netting agreements equal carrying amount financial assets plus positive fair value derivative instruments credit exposure diversified amongst different counterparties december groups combined trade accounts receivable balance three us national wholesale distributors amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss francs representing groups consolidated trade accounts receivable billion swiss francs representing liquidity risk group companies require sufficient availability cash meet obligations individual companies generally responsible cash management including shortterm investment cash surpluses raising loans cover cash deficits subject guidance group certain cases approval group level group maintains sufficient reserves cash readily realisable marketable securities meet liquidity requirements times addition strong international creditworthiness group provides ability efficiently use international capital markets financing purposes group unused committed credit lines various financial institutions totalling billion swiss francs includes syndicated credit facility billion euros bank commitment lines billion japanese yen chugai finance report roche group notes roche group consolidated financial statements segment information divisional information millions chf roche pharmaceuticals genentech chugai segment revenues segment revenuesdivisional sales less interdivisional sales divisional sales third parties segment results operating profit exceptional items major legal cases segment resultsoperating profit segment assets liabilities divisionalsegment assets nonsegment assets total assets divisional liabilities segment liabilities segment liabilities nonsegment liabilities total liabilities segmental expense information research development costs equity compensation plan expenses restructuring expenses capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets income associated companies investments associated companies finance report roche group notes roche group consolidated financial statements pharmaceuticals diagnostics division division corporate group finance report roche group notes roche group consolidated financial statements information geographical segment millions chf sales third parties destination segment assets capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total genentech effective september group acquired majority interest approximately genentech inc biotechnology company united states june group exercised option acquire remaining shares genentech june point genentech became owned subsidiary group july october march group completed public offerings genentechs common stock reduced groups majority interest groups ownership genentech decreased due conversion redemption lyons iv us dollar exchangeable notes genentech issues additional shares common stock connection equity compensation plans also may issue additional shares purposes affects groups percentage ownership interest affiliation agreement group genentech provides amongst things genentech establish stock repurchase programme maintain groups percentage ownership interest genentech december groups interest genentech finance report roche group notes roche group consolidated financial statements common stock genentech publicly traded listed new york stock exchange symbol dna genentech prepares financial statements conformity accounting principles generally accepted united states us gaap filed quarterly basis us securities exchange commission sec differences ifrs us gaap due certain consolidation entries differences requirements international financial reporting standards ifrs us gaap differences genentechs standalone financial results us gaap basis financial results genentech consolidated roche group accordance ifrs reconciliation genentech results usd chf usd chf millions millions millions millions operating income us gaap basis redemption costs equity compensation plan expenses us gaap basis special litigation items operating income nonus gaap basis add deduct differences consolidation entries add back redemption costs equity compensation plan expenses ifrs basis capitalised inprocess research development differences consolidation entries operating profit exceptional items ifrs basis add deduct exceptional items major legal cases segment resultoperating profit ifrs basis add deduct nonoperating items ifrs basis financial income financing costs income taxes net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis translated usd chf usd chf effective january group implemented ifrs sharebased payment ifrs financial statements amongst matters standard requires fair value equity compensation plans awarded employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading standard also requires retrospective application within certain transitional requirements pretax expense million us dollars million swiss francs relating plans genentech recorded million us dollars million swiss francs due impact transitional requirements amounts indicative future expenses plans effective january genentech implemented us statement financial accounting standards r sharebased payment fas r us gaap financial statements amongst matters requires companies reporting us gaap recognise compensation expenses plans due different dates first application measurement requirements transitional arrangements fas r ifrs expenses recorded genentech us gaap financial statements equity compensation plans expenses recorded roche group ifrs financial statements plans finance report roche group notes roche group consolidated financial statements group implemented ias revised intangible assets ifrs financial statements amongst matters revised standard typically results intangible assets recognised inlicensing arrangements similar research development alliances genentechs us gaap financial statements expenditure would usually recorded research development expenses differences ifrs us gaap relatively minor impact genentech share repurchases april genentechs board directors approved extension existing stock repurchase programme authorising genentech repurchase million shares genentechs common stock total billion us dollars june since programmes inception genentech repurchased approximately million shares total approximately billion us dollars genentech repurchased common stock worth million us dollars million swiss francs million us dollars million swiss francs manufacturing agreements lonza effective december genentech sold whollyowned subsidiary genentech espaa including manufacturing facility porrio spain lonza group ltd lonza million us dollars million us dollars received cash remaining balance received lonza series payments next three years part agreement genentech entered shortterm supply contract lonza production avastin using portion production capacity porrio facility loss divestment genentech espaa millions chf consideration cash present value unsecured receivables lonza total consideration net assets disposed property plant equipment net assets loss divestment time genentech entered supply agreement manufacture certain genentech products lonzas facility construction singapore currently expected receive us food drug administration fda licensure genentech committed fund precommissioning production qualification costs facility upon fda licensure genentech committed purchase products successfully manufactured facility period three years commissioning facility estimated total cost pre postcommissioning commitments approximately million us dollars genentech also received exclusive option purchase lonza singapore facility period one year fda licensure purchase price million us dollars regardless whether purchase option exercised genentech obliged make milestone payment million us dollars certain performance milestones met facility constructed genentech also entered loan agreement lonza advance million us dollars lonza construction singapore facility majority expected advanced majority funds advanced lonza unless lonzas securitisation obligations mutually agreed upon parties genentech exercises option purchase facility outstanding advances may offset purchase price genentech exercise purchase option advances may offset supply purchases finance report roche group notes roche group consolidated financial statements oceanside biologics manufacturing facility june genentech completed purchase oceanside biologics manufacturing facility san diego california biogen idec purchase cost including closing costs million swiss francs acquisition tanox november genentech announced plans acquire controlling interest tanox inc tanox publicly owned company listed nasdaq symbol tnox tanox biotechnology company based houston texas specialises discovery development biotherapeutics based monoclonal antibody technology genentech tanox working together collaboration novartis since develop commercialise xolair expected purchase consideration excluding transaction costs million us dollars cash funds provided genentechs cash hand thetime closing january transaction approved tanoxs shareholders transaction subject regulatory clearance expected completed first half leasing arrangements third quarter genentech paid million us dollars buy lease obligations respect manufacturing facility vacaville california certain buildings south san francisco site december genentech entered master lease agreement slough ssf llc slough development property adjacent genentechs south san francisco site development includes total eight buildings subject separate agreements contemplated master lease agreement slough developer construct building shell building genentech finish interior building laboratory office space applicable construction first buildings completed point lease term buildings deemed begin construction final buildings expected completed lease term expires twelve years occupation final building genentech two fiveyear renewal options building option purchase various buildings different dates genentech also right first refusal respect building entire development slough consider selling part development december based status development date total carrying value property plant equipment agreement including tenant improvements million swiss francs carrying value leasing obligation million swiss francs estimates total future minimum lease payments anticipated entire master lease agreement shown estimated total future minimum lease payments slough leases millions chf total minimum principal ground lease interest lease payments within one year one five years five years total matters details genentech legal cases given note details genentechs equity compensation plans given note details genentechs senior notes given note chugai effective october roche group chugai completed alliance create leading research driven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai fully consolidated subsidiary group december groups interest chugai finance report roche group notes roche group consolidated financial statements common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements conformity accounting principles generally accepted japan jgaap filed quarterly basis tokyo stock exchange differences ifrs jgaap due certain consolidation entries differences requirements international financial reporting standards ifrs jgaap differences chugais standalone financial results jgaap basis financial results chugai consolidated roche group accordance ifrs acquisition roche interest chugai treated business combination ifrs jgaap alliance treated merger chugai nippon roche therefore jgaap results chugai include goodwill fair value adjustments recorded roches results quantified table moreover acquisition accounting includes roches fair value adjustments therefore impact net income needs added back minority interest calculations roches ifrs results roches ifrs results depreciation property plant equipment calculated using straightline method chugais jgaap results reducing balance method used additionally certain income expenses notably restructuring costs required jgaap reported extraordinary items chugais jgaap results extraordinary items reported operating profit line roches ifrs results items normally included part operating profit treated extraordinary exceptional items restructuring costs million swiss francs million swiss francs differences ifrs jgaap relatively minor impact reconciliation chugai results jpy chf jpy chf billions millions billions millions operating profit jgaap basis depreciation basis difference classification extraordinary items differences consolidation entries chugai operating profit exceptional items acquisition accounting impacts ifrs basis depreciation property plant equipment amortisation intangible assets arising business combinations chugai operating profit exceptional items ifrs basis add deduct exceptional items major legal cases chugai segment resultoperating profit ifrs basis add deduct corporate nonoperating items ifrs basis gain settlement defined benefit plans financial income financing costs income taxes net income ifrs basis minority interest calculation add back acquisition accounting impact net income net income excluding acquisition accounting minority interest percentage average year income applicable minority interest ifrs basis translated jpy chf jpy chf finance report roche group notes roche group consolidated financial statements dividends dividends distributed third parties holding chugai shares including special dividends totalled million swiss francs million swiss francs recorded minority interests see note dividends paid chugai roche eliminated consolidation intercompany items restructuring production facilities february chugai announced restructuring production facilities five existing plants integrated two facilities within next five six years part restructuring plant kagamiishi sold first half total restructuring costs including loss disposal kagamiishi plant million swiss francs shown extraordinary loss chugaisjgaap financial statements pensions postemployment benefits second half chugai returned part employees pension fund japanese government result settlement gain million swiss francs accordance groups management organisational structure reported general administration expenses within corporate business segment results shown extraordinary gain chugais jgaap financial statements matters details chugais equity compensation plans given note details series chugai pharmaceutical unsecured convertible bonds including conversions year given note royalties operating income royalties operating income millions chf pharmaceuticals diagnostics group royalty income income outlicensing agreements gains disposal products total royalties operating income income outlicensing agreements certain group companies receive third parties upfront milestone similar payments relating sale licensing products technology revenue associated performance milestones recognised based achievement milestones defined respective agreements revenue upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation gains disposal products part continuous realignment product portfolio group periodically disposes product lines longer considered core products priorities within product development portfolio proceeds reinvested groups inlicensing arrangements research development alliances collaborations finance report roche group notes roche group consolidated financial statements major legal cases income expenses major legal cases millions chf roche pharmaceuticals legal cases genentech legal cases diagnostics legal cases total income expenses major legal cases continuing businesses discontinued businesses vitamin case group total income expenses major legal cases continuing businesses disclosed separately income statement due materiality amounts order fairly present groups results total net cash outflow major legal cases year million swiss francs million swiss francs roche pharmaceuticals legal cases roche diagnostics gmbh rdg smithkline beecham cork ltd sb party arbitration concerning rdgs termination carvedilol license agreement amended relating licensing comarketing carvedilol rdg submitted two claims damages two arbitration tribunals zurich sb submitted counterclaim asserting invalidity rdgs termination claiming damages based development current arbitration settlement negotiations group increased existing provisions million swiss francs developments would require changes provisions already recorded group total amount provisions recorded rdg disclosed may seriously prejudice rdgs position matter genentech legal cases june genentech announced los angeles county superior court jury voted award city hope medical center city hope approximately million us dollars compensatory damages based finding breach agreement genentech city hope june jury voted award city hope million us dollars punitive damages case september genentech filed notice appeal jury verdict damages awards california court appeal october court appeal affirmed verdict damages awards respects also october genentech announced would seek review california supreme court discretion cases review november genentech filed petition review california supreme court february california supreme court granted petition appeal california supreme court fully briefed genentech waiting assigned oral argument date full provision classified longterm recorded damages awards appeals process interest accrues total amount damages simple annual rate following judgement interest million swiss francs million swiss francs recorded time cost provisions within financing costs october genentech entered arrangement withthirdparty insurance companies post surety bond connection judgement part arrangement genentech pledged million us dollars cash investments secure bond december increased million us dollars million us dollars amount equivalent million swiss francs december reported restricted cash within financial long term assets see note october genentech received subpoena united states department justice requesting documents related promotion rituxan prescription product approved treatment relapsed refractory lowgrade follicular cdpositive bcell nonhodgkins lymphoma genentech cooperating associated investigation genentech advised civil criminal nature government called expected call former current genentech employees appear grand jury connection investigation provisions recorded respect litigation outcome matter determined time finance report roche group notes roche group consolidated financial statements april medimmune inc medimmune filed lawsuit genentech city hope national medical center celltech rd ltd us district court central district california los angeles lawsuit relates us patent cabilly patent coowned genentech city hope national medical center medimmune companies licensed paying royalties lawsuit includes claims violation antitrust patent unfair competition laws january us district court granted summary judgement medimmunes antitrust andunfair competition claims april district court granted motion dismiss remaining claims case october us court appeals federal circuit affirmed judgement district court respects november medimmune filed petition us supreme court seeking review decision dismiss certain claims supreme court granted medimmunes petition oral argument case supreme court occurred october january supreme court issued decision reversing federal circuits decision remanding case lower courts proceedings decision addresses issue whether medimmunes patent contract claims go forward federal court expresses opinion regarding merits claims provisions recorded respect litigation outcome matter determined time may request filed third party reexamination cabilly patent july us patent trademark office ordered reexamination patent september patent office issued initial nonfinal office action rejecting claims patent genentech filed response november patent office yet acted response second reexamination request patent filed december another third party january patent office granted reexamination request june two reexaminations combined patent office single reexamination august patent office issued nonfinal office action merged proceeding rejecting claims cabilly patent based issues raised two reexamination requests genentech filed response october patent office yet acted response cabilly patent expires relates methods used genentech others make certain antibodies antibody fragments well cells dna used methods genentech licensed cabilly patent companies derives significant royalties licences claims cabilly patent remain valid enforceable throughout reexamination process examination process ongoing provisions recorded respect litigation final outcome matter determined time july former genentech employee whose employment ended april filed nonpublic qui tam complaint seal united states district court district maine genentech biogen idec alleging violations false claims act retaliatory discharge employment december united states district court filed notice election decline intervention lawsuit complaint subsequently unsealed genentech served january genentech filed motion dismiss complaint december magistrate judge issued recommended decision motion magistrate judge recommended granting genentechs motion dismiss former employees qui tam claims recommended denying genentechs motion solely former employees claim retaliatory discharge employment parties filed objections district court judge concerning portions magistrate judges recommended decision review district court judge sought provisions recorded respect litigation potential outcome determined time march mr kourosh dastghieb filed lawsuit genentech us district court eastern district pennsylvania lawsuit relates dastghiebs claim based relationship genentech mids entitled profits proceeds genentechs lucentis product dastghieb asserted multiple claims monetary damages including claim unjust enrichment theory entitled entire net present value lucentis claims approximately billion us dollars billion us dollars november unanimous jury ruled dastghieb favour genentech claims final judgement entered genentechs favour plaintiff filed motion challenge judgement set hearing early provisions recorded respect litigation potential outcome determined time finance report roche group notes roche group consolidated financial statements genentechs annual report quarterly sec filings contain detailed disclosures litigation matters required us gaap include details matters well including information litigation currently significant matters referred diagnostics legal cases provisions certain litigation arbitration matters diagnostics division increased million swiss francs developments would require changes tothe provisions already recorded group october applera corporation applera filed suit group superior court california filed notice arbitration american arbitration association superior court lawsuit arbitration demand made claims concerning interpretation enforcement contracts group applera commercialisation polymerase chain reaction pcr technology claims sought termination certain contracts declarations regarding rights obligations contracts monetary damages relief unspecified amount alleged breaches various agreements parties december group filed response arbitration proceeding day group also responded appleras complaint superior court proceeding petitioning court compel arbitration claims alleged applera stay lawsuit pending completion arbitration october court appeal state california ruled petition compel arbitration granted remanded case superior court directions grant petition may group announced settlement agreement reached applera regard outstanding litigation arbitration related contractual relationships involving rights commercialisation polymerase chain reaction pcr technology group filed suit promega corporation promega alleging patent infringement breach licence agreement relating polymerase chain reaction pcr technology may us district court northern district california decided one patents concerned unenforceable rejected breach licence claim november group notified promega filed nonpublic qui tam action group us district court eastern district west virginia march complaint filed false claims act alleged us federal government overcharged purchase pcr enzyme products july us federal government notified court decision intervene promegas complaint november court ordered complaint unsealed group filed motion dismiss complaint august thecourt dismissed complaint prejudice september group announced settlement agreement reached promega regard outstanding litigation related polymerase chain reaction pcr technology vitamin case following settlement agreement us department justice may regarding pricing practices vitamin market overall settlement agreement class action suit brought us buyers bulk vitamins group recorded provisions respect vitamin case provisions groups best estimate time total liability may arise taking account currency movements time value money provisions legal fees recorded separately group recorded additional provisions based development litigation settlement negotiations us europe elsewhere january district columbia circuit court appeals ruled class action litigation brought behalf nonus purchasers bulk vitamins group manufacturers nonus plaintiffs may bring claims us courts us antitrust laws alleged damages suffered transactions outside united states june supreme court united states nullified decision district columbia circuit court appeals supreme court remanded case lower court review alternative arguments might permit claims proceed united states remand june panel district columbia circuit court appeals ruled unanimously us courts jurisdiction plaintiffs claims affirmed initial dismissal complaint october plaintiffs petitioned us supreme court discretionary review january us supreme court finance report roche group notes roche group consolidated financial statements issued order denying plaintiffs petition march plaintiffs filed motion trial court seeking relief final judgement plaintiffs could advance european union law claims trial court trial court denied motion plaintiffs time appeal trial courts ruling expired group considers matter closed group seeking resolve remaining outstanding issues however timing final amounts involved uncertain remaining provisions considered shortterm cash outflows expected arise discounted time value money considered material case litigation negotiations progress possible ultimate liability may different amount provisions currently recorded financial income financing costs financial income millions chf year ended december gains sale equity securities losses sale equity securities dividend income gains losses equity derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities net gains losses financial assets fairvaluethroughprofitorloss writedowns impairments longterm loans net interest income income debt securities expected return plan assets defined benefit plans foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total financial income financing costs millions chf year ended december interest expense amortisation discount debt instruments gains losses interest rate derivatives net net gains losses financial liabilities fairvaluethroughprofitorloss time cost provisions interest cost defined benefit plans total financing costs finance report roche group notes roche group consolidated financial statements net financial income millions chf year ended december financial income financing costs net financial income financial result treasury management financial result pension management net financial income net gains losses financial liabilities fairvaluethroughprofitorloss includes change fair value attributable changes liabilities credit risk component calculated comparing difference present value future cash flows bonds discounted using swap libor yield curve market prices bonds due major credit spread movement relative swap yield curve change fair value attributable changes liabilities credit risk component zero loss million swiss francs cumulative change fair value attributable change credit risk since issuance instruments gain million swiss francs gain million swiss francs interest expense liabilities fairvaluethroughprofitorloss million swiss francs million swiss francs income taxes income tax expenses millions chf current income taxes adjustments recognised current tax prior periods deferred income taxes total charge income taxes since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate millions chf average expected tax rate tax effect utilisation previously unrecognised tax losses nontaxable incomenondeductible expenses genentech equity compensation plans differences continuing businesses exceptional items effective tax rate profit income tax profit income tax tax taxes rate tax taxes rate roche excluding genentech chugai genentech chugai continuing businesses exceptional items effective tax rate major legal cases groups effective tax rate finance report roche group notes roche group consolidated financial statements income tax assets liabilities millions chf current income taxes current income tax assets current income tax liabilities net current income tax asset liability deferred income taxes deferred income tax assets deferred income tax liabilities net deferred income tax asset liability deferred income tax assets recognised tax loss carry forwards extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry millions chf within one year one five years five years total unrecognised tax losses deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable following items deferred income taxes movements recognised net assets liabilities millions chf property plant equipment temporary intangible assets differences total year ended december net deferred income tax asset liability january previously reported changes accounting policy net deferred income tax asset liability january restated charged credited income statement charged credited equity recognised gains losses charged credited equity equity compensation plans transactions shareholders acquisition glycart currency translation effects net deferred income tax asset liability december finance report roche group notes roche group consolidated financial statements property plant equipment temporary intangible assets differences total year ended december net deferred income tax asset liability january charged credited income statement charged credited equity recognised gains losses charged credited equity equity compensation plans transactions shareholders currency translation effects net deferred income tax asset liability december business combinations net cash outflows acquisitions subsidiaries associated companies millions chf glycart acquisitions total net cash outflows acquisitions amounts net cash balances acquired company acquisitions acquisitions november genentech announced plans acquire controlling interest tanox inc us biotechnology company transaction expected close thefirst half subject regulatory approval described note acquisitions glycart effective july group acquired controlling interest glycart biotechnology ltd glycart privatelyowned biotechnology research company based schlieren zurich switzerland glycart reported part roche pharmaceuticals business segment purchase consideration paid million swiss francs allocated follows glycart acquisition net assets acquired millions chf carrying value carrying value prior acquisition upon acquisition goodwill intangible assets inprocess research development intangible assets core technology property plant equipment deferred income taxes cash net assets liabilities total goodwill recognised resulting premium paid acquisition represents synergies obtained groups existing business utilising acquired core technology intangible assets core technology amortised straightline basis years beginning august intangible assets inprocess research development amortised useful lives straightline basis beginning point available use subsequent acquisition glycart contributed net expense million swiss francs roche pharmaceuticals business result glycart acquired january revenues group would unchanged groups net income would lower million swiss francs compared reported results finance report roche group notes roche group consolidated financial statements discontinued businesses profit discontinued businesses millions chf consumer vitamins consumer vitamins health fine health fine otc chemicals total otc chemicals total segment revenues expenses operating profit exceptional items operating profit financing costs profit taxes income taxes business result gain loss disposal income taxes profit disposal profit discontinued businesses earnings per share nonvoting equity security basic chf diluted chf assets liabilities discontinued businesses millions chf consumer vitamins consumer vitamins health fine health fine otc chemicals total otc chemicals total property plant equipment longterm assets current assets total assets provisions noncurrent liabilities current liabilities total liabilities net assets significant cash flows discontinued businesses millions chf consumer vitamins consumer vitamins health fine health fine otc chemicals total otc chemicals total operating cash flows major legal cases proceeds disposal total significant cash inflows outflows finance report roche group notes roche group consolidated financial statements divestment consumer health otc business july group announced sale roche consumer health global otc overthecounter medicines business bayer group agreement bayer majority local businesses transferred bayer end divestment remaining measured terms roche consumer health sales third parties completed terms agreement majority cash proceeds totalling million swiss francs transferred group january addition group received million swiss francs first half remaining part divestment completed calculations final amounts arising agreed purchase price adjustment mechanisms completed result million swiss francs transferred bayer effect net income transfer amounts concerned covered accruals made initial calculation gain disposal profit disposal consists release million swiss francs respect certain accruals andprovisions longer required business results include remaining part roche consumer health transferred bayer significant cash flows receipt divestment proceeds received bayer described divestment vitamins fine chemicals business effective september group completed sale global vitamins fine chemicals business vfc business dutch company dsm following sale vfc business certain assets liabilities vitamins fine chemicals division mainly associated vitamin case remain group group dsm signed indemnity cooperation agreement group may provide dsm certain indemnities guarantees connection vitamin case addition group given dsm certain indemnities respect anyremedial actions sites vfc business may required environmental laws arrangements put place regarding utilisation certain assets certain purchasing contracts well adopting dsm preferred supplier pharmaceutical ingredients one arrangements group guaranteed purchase period four years beginning january products sales value totalling million euros group reimburse dsm unutilised amounts arrangements consist certain residual obligations fully accrued profit disposal consists release million swiss francs respect certain accruals provisions longer required business results include costs million swiss francs million swiss francs due mostly aftertax amortisation discounted liabilities employee benefits employee remuneration millions chf wages salaries social security costs defined contribution postemployment plans operating expenses defined benefit postemployment plans equity compensation plans employee benefits employees remuneration included operating results expected return plan assets defined benefit postemployment plans interest cost defined benefit postemployment plans total employees remuneration finance report roche group notes roche group consolidated financial statements employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits charges employee benefits operating results included relevant expenditure line function expected return plan assets interest costs defined benefit plans included part financial income financing costs respectively see note pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees atthe time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements economic conditions countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising consequently groups postemployment benefit plans classified defined benefit plans purpose financial statements defined contribution plans defined contribution plans typically consist payments employees group funds administered third parties payments group million swiss francs million swiss francs assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions defined benefit plans groups major defined benefit plans located switzerland united states germany united kingdom japan plans usually established trusts independent group funded payments group employees cases notably major defined benefit plans germany plan unfunded group pays pensions retired employees directly financial resources current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate business segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses recorded directly equity recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly equity finance report roche group notes roche group consolidated financial statements defined benefit plans expenses millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total current service cost past service cost gain loss curtailment gain loss settlement total operating expenses expected return plan assets interest cost total financial income expense total expense recognised income statement funding groups various defined benefit plans overseen corporate level qualified independent actuaries carry valuations regular basis major plans annually balance sheet date funded plans usually trusts independent groups finances net assetliability recognised groups balance sheet corresponds overunder funding plan adjusted unrecognised past service costs unfunded plans group meets pension obligations directly financial resources liability defined benefit obligation recorded groups balance sheet pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan recognition pension assets limited present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs amounts recognised balance sheet postemployment benefits predominantly noncurrent reported noncurrent assets liabilities defined benefit plans funding status december millions chf funded unfunded funded unfunded plans plans total plans plans total fair value plan assets defined benefit obligation funding unrecognised past service costs limit asset recognition reimbursement rights net recognised asset liability reported postemployment benefit assets postemployment benefit liabilities reimbursement rights net recognised asset liability detailed information plan assets defined benefit obligation given finance report roche group notes roche group consolidated financial statements defined benefit plans fair value plan assets millions chf january expected return plan assets actuarial gains losses currency translation effects employer contributions employee contributions benefits paid funded plans past service cost business combinations curtailments settlements december invested shares equity instruments bonds debentures debt instruments property assets total included within fair value plan assets thousand groups nonvoting equity securities fair value million swiss francs thousand nonvoting equity securities written call options total fair value million swiss francs defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost employee contributions actuarial gains losses currency translation effects benefits paid funded plans benefits paid unfunded plans past service cost business combinations curtailments settlements december funded plans unfunded plans part cost certain groups postemployment plans reimbursed government programmes reimbursement rights reported longterm assets see note totalled million swiss francs december million swiss francs movements reimbursement rights primarily consist currency translation effects million swiss francs finance report roche group notes roche group consolidated financial statements actuarial assumptions actuarial assumptions unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters salary benefit levels interest rates return investments costs medical benefits group operates defined benefit plans many countries actuarial assumptions vary based upon local economic social conditions demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity mortality tables used major schemes germany heubeck tables g japan national census life table switzerland swiss bvg united kingdom nonpensioners pac rated one year united kingdom pensioners pac rated one year united states rp projected rates employee turnover disability early retirement based historical behaviour within group companies financial assumptionsthese based market expectations period obligations settled ranges assumptions used actuarial valuations significant plans areincountries stable currencies interest rates shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates return plan assets expected rates salary increases medical cost trend rate discount rates used calculate discounted present value defined benefit obligation determined reference market yields high quality corporate bonds government bonds countries deep market corporate bonds currency term bonds consistent obligation discounted interest cost included income statement calculated multiplying discount rate defined benefit obligation expected returns plan assets based market expectations expected returns assets funded plans duration related obligation takes account split plan assets equities bonds property investments calculation includes assumptions concerning expected dividend interest income realised unrealised gains plan assets taxes administration costs borne plan based longterm market expectations actual performance continually monitored corporate management due longterm nature obligations assumptions used matters returns investments may necessarily consistent recent historical patterns expected return plan assets included income statement calculated multiplying expected rate return fair value plan assets difference expected return actual return twelve month period actuarial gainloss recorded directly equity actual return plan assets million swiss francs million swiss francs expected rates salary increases used calculate defined benefit obligation current service cost included income statement based latest expectation historical behaviour within group companies finance report roche group notes roche group consolidated financial statements medical cost trend rates used calculate defined benefit obligation current service cost included income statement postemployment medical plans take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments united states effect one percentage point increase decrease medical cost trend rate shown defined benefit plans sensitivity medical cost trend rate millions chf current service cost interest cost defined benefit obligation funding summary fiveyear summary funding status groups defined benefit plans shown table defined benefit plans summary funding status millions chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation increase decrease funding status arising experience adjustments fair value plan assets defined benefit obligation increase decrease funding status arising changes actuarial assumptions fair value plan assets defined benefit obligation cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately million swiss francs amounts recorded equity actuarial gains losses recognised statement recognised income expense gains million swiss francs losses million swiss francs cumulative amount december gains million swiss francs losses million swiss francs addition recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit asset recognition recorded directly equity adjustment million swiss francs zero finance report roche group notes roche group consolidated financial statements employee stock options equity compensation benefits group operates several equity compensation plans including separate plans genentech chugai effective january group adopted ifrs sharebased payment amongst matters standard requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expense share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche performance share plan roche stock appreciation rights total equity compensation plans total operating expense equitysettled cashsettled cash inflow outflow equity compensation plans millions chf share option plans roche option plan genentech stock option plan chugai stock acquisition rights total share option plans equity compensation plans roche connect genentech employee stock purchase program roche stocksettled stock appreciation rights roche performance share plan roche stock appreciation rights total equity compensation plans total cash inflow outflow equitysettled cashsettled finance report roche group notes roche group consolidated financial statements roche longterm group implemented new global longterm incentive programme available certain directors management employees selected discretion group programme consists stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan share option plans roche option planawards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note introduction roche longterm number options granted roche option plan significantly reduced eligible employees receive roche stocksettled stock appreciation rights instead roche option plan movement number options outstanding number weighted average number weighted average options exercise price options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable weighted weighted number weighted average average number average outstanding years remaining exercise exercisable exercise year grant thousands contractual life price chf thousands price chf total genentech stock option planthe genentech stock option plan adopted amended thereafter april genentechs shareholders approved equity incentive plan plans allow granting various stock options incentive stock options stock purchase rights employees directors consultants genentech incentive stock options stock purchase rights granted plan date options granted nontradable equitysettled awards tenyear duration vest phased basis four years subject continued employment finance report roche group notes roche group consolidated financial statements genentech stock option plan movement number options outstanding number number options weighted average options weighted average millions exercise price usd millions exercise price usd outstanding january granted forfeited exercised expired outstanding december exercisable genentech stock option plan terms options outstanding december options outstanding options exercisable weighted weighted number weighted average average number average range exercise prices outstanding years remaining exercise exercisable exercise usd millions contractual life price usd millions price usd total chugai stock acquisition rights chugai adopted stock acquisition rights programme programme allows granting rights employees directors chugai right entitles holder purchase chugai shares specified exercise price options nontradable equitysettled awards tenyear duration vest two years chugai stock acquisition rights movement number rights outstanding number weighted average number weighted average options exercise price jpy options exercise price jpy outstanding january granted forfeited exercised expired outstanding december exercisable chugai stock acquisition rights terms rights outstanding december rights outstanding rights exercisable weighted weighted weighted average average average number years remaining exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy total finance report roche group notes roche group consolidated financial statements issues share options issues share options including methodology used calculate fair value main inputs valuation models described issues share option plans roche genentech stock chugai stock option plan option plan acquisition rights number options granted thousand million underlying equity roche nonvoting genentech common chugai shares equity securities stock blocks currency swiss francs us dollars japanese yen vesting period progressively progressively years years years contractual life years years years weighted average fair value options issued option pricing model used binomial binomial binomial inputs option pricing model share price grant date exercise price expected volatility expected dividend yield early exercise factor na expected exit rate volatility determined reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour chugai grants assumed awards would held full term length since insufficient historically observed early exercise behaviour equity compensation plans roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held thousand nonvoting equity securities thousand programme operational since october year cost plan million swiss francs million swiss francs reported within relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allows employees purchase genentechs common stock lower market value grant date purchase date total million shares genentech common stock purchased million shares resulting cash inflow million swiss francs million swiss francs year cost plan million swiss francs million swiss francs reported within relevant expenditure line function finance report roche group notes roche group consolidated financial statements roche stocksettled stock appreciation rightswith introduction roche longterm group offers stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date options nontradable equitysettled awards seven year duration vest phased basis three years subject continued employment group covers obligations purchasing nonvoting equity securities derivatives thereon see note roche ssars movement number rights outstanding number number rights weighted average rights weighted average thousands exercise price chf thousands exercise price chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable weighted weighted number weighted average average number average outstanding years remaining exercise exercisable exercise year grant thousands contractual life price chf thousands price chf total weighted average fair value options granted calculated using binomial model inputs model consistent used roche option plan awards given previously resulting weighted average fair value per right chf giving total fair value million swiss francs charged vesting period three years roche performance share planthe group offers future nonvoting equity security awards boards discretion cash equivalent certain directors key senior managers programme established beginning effect three years board approved new threeyear cycle roche performance share plan psp operate amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares non voting equity securities combined relative groups peers threeyear period date grant discretion board directors cycle total thousand awards made nontradable equitysettled awards award result zero two non voting equity securities depending upon achievement performance targets allocated recipients february fair value per one unit psp cycle chf giving total fair value million swiss francs charged vesting period three years finance report roche group notes roche group consolidated financial statements board approved threeyear cycle roche performance share plan psp operate terms conditions similar cycle cycle total thousand awards made nontradable equitysettled awards award result zero two nonvoting equity securities depending upon achievement performance targets allocated recipients february weighted average fair value awards granted calculated using monte carlo simulation input parameters model covariance matrix roche individual companies peer group based threeyear history risk free rate valuation also takes account defined rank performance structure determines payout psp resulting value per one unit psp cycle chf giving total fair value million swiss francs charged vesting period three years roche stock appreciation rights employees certain north american subsidiaries group receive stock appreciation rights sars part compensation sars nontradable cash settled awards may exercised vesting period one three years cash payment based upon amount market price groups american depositary receipts adrs point ofexercise exceeds strike price grant price issuance following implementation roche longterm see group plan award cashsettled sars awards made roche stock appreciation rights millions chf liability december intrinsic value vested rights december roche stock appreciation rights terms rights outstanding december rights outstanding rights exercisable weighted weighted number average number average outstanding exercise exercisable exercise year grant thousands expiry price usd thousands price usd total fair value december calculated using binomial model inputs model adr price december usd exercise prices given table inputs consistent used roche option plan awards given previously finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction improve land ments equipment progress total january cost accumulated depreciation impairment net book value year ended december january glycart acquisition disposal consumer health otc business additions disposals transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january additions disposals divestment genentech espaa transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence could result shortened useful lives impairment leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets million swiss francs million swiss francs finance report roche group notes roche group consolidated financial statements finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value future payments minimum lease payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted addition genentech leasing arrangements disclosed note operating leasesgroup companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swiss francs million swiss francs operating leases future minimum lease payments noncancellable leasesin millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leasescertain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method finance leases future minimum lease payments noncancellable leases millions chf present value future gross investment lease minimum lease payments within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments million swiss francs million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straight line basis finance report roche group notes roche group consolidated financial statements operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments december machinery equipment original cost million swiss francs million swiss francs net book value million swiss francs million swiss francs leased third parties contingent rent recognised income capital commitments group capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs addition genentechs capital commitments respect manufacturing agreements lonza leasing arrangements described note goodwill goodwill movements carrying value assets millions chf january glycart acquisition acquisitions impairment charge currency translation effects december allocated following cashgenerating units pharmaceuticals division roche pharmaceuticals genentech chugai total pharmaceuticals division diagnostics division diabetes care centralized diagnostics molecular diagnostics near patient testing applied science corangeboehringer mannheim held divisional level allocated business areas total diagnostics division total group accumulated impairment losses goodwill goodwill arising investments associated companies classified part investments associated companies see note finance report roche group notes roche group consolidated financial statements goodwill impairment testing pharmaceuticals divisionthe divisions reportable business segments cashgenerating units used testing goodwill genentech chugai recoverable amount based fair value less costs sell determined reference publicly quoted share prices genentech chugai shares goodwill roche pharmaceuticals business significant comparison groups total carrying amount goodwill diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition recorded monitored divisional level meaningfully allocated divisions business areas therefore cash generating unit goodwill entire division recoverable amount used impairment testing based value use cash flow projections used based recent business plans approved management assume significant changes organisation division include managements latest estimates sales volume pricing production operating costs reflect past experience projected five years discount rate used based rate derived capital asset pricing model using data swiss capital markets including swiss federal government year bonds smi index adjusted pretax rate management believes reasonably possible change key assumptions would cause carrying value goodwill exceed recoverable amount intangible assets intangible assets movements carrying value assets millions chf patents licences trademarks intangible assets arising business combinations total january cost accumulated amortisation impairment net book value year ended december january glycart acquisition additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value finance report roche group notes roche group consolidated financial statements patents licences trademarks intangible assets arising business combinations total year ended december january additions disposals amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated following business segments roche pharmaceuticals genentech chugai diagnostics total group included roche pharmaceuticals business segment intangible assets carrying value million swiss francs remaining amortisation period years relate purchase group global rights kytril granisetron diagnostics business segment includes intangible assets carrying value million swiss francs remaining amortisation period years relate acquisition corangeboehringer mannheim intangible assets carrying value million swiss francs remaining amortisation period years relate acquisition igen intangible assets yet available use mostly arise groups inlicensing arrangements total million swiss francs total million swiss francs relate roche pharmaceuticals business segment group currently internally generated intangible assets development criteria recognition asset met impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment second half group recorded impairment charges million swiss francs relating intangible assets diagnostics division followed regular updating divisions business plans technology assessments second half indicated anticipated recoverable amounts current carrying values certain assets mainly concern certain intangible assets recorded following disetronic acquisition assets written recoverable amount based value use calculation using discount rate additionally remaining useful life assets reassessed reduced years years effective december consequent matters group expects amortisation charge intangible assets diagnostics division approximately million swiss francs lower would otherwise roche pharmaceuticals business segment impairment charge million swiss francs recorded second half relates decision terminate development one compound alliance partner asset concerned yet amortised fully writtendown charge finance report roche group notes roche group consolidated financial statements associated companies groups investments associated companies accounted using equity method goodwill arising investments associated companies classified part investments associated companies investments associated companies millions chf share net income balance sheet value total investments associated companies group significant investments associated companies material transactions group associated companies additional information associated companies given note financial longterm assets financial longterm assets millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets prepaid employee benefits reimbursement rights postemployment benefit plans total longterm assets financial longterm assets held strategic purposes classified noncurrent availablefor sale investments mainly equity investments unquoted equity investments classified availableforsale generally measured cost fair value measured reliably primarily investments private biotechnology companies kept part groups strategic alliance efforts carrying value equity investments held cost million swiss francs million swiss francs average effective interest rate heldtomaturity investments loans receivable comprise loans third parties term one year restricted cash primarily consists surety bond posted genentech connection city hope litigation see note december million swiss francs million swiss francs inventories inventories millions chf raw materials supplies work process finished goods intermediates less provision slowmoving obsolete inventory total inventories expenses relating inventories expensed cost sales totalled million swiss francs expenses relating inventories totalled million swiss francs million swiss francs expensed cost sales million swiss francs relating consumer health otc business expensed profit discontinued businesses finance report roche group notes roche group consolidated financial statements accounts receivable accounts receivable millions chf trade accounts receivable notes receivable less allowances total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs following recovery previously provided amounts group recorded net income bad debts million swiss francs net bad debt expense million swiss francs significant concentrations within trade receivables counterparty credit risk described note current assets current assets millions chf accrued interest income prepaid expenses derivative financial instruments restricted cash receivables total current assets marketable securities marketable securities millions chf financial assets fairvaluethroughprofitorloss heldfortrading investments bonds debentures designated fairvaluethroughprofitorloss bonds debentures investments total financial assets fairvaluethroughprofitorloss availableforsale financial assets shares bonds debentures money market instruments time accounts three months total availableforsale financial assets total marketable securities marketable securities held fund management purposes classified current primarily denominated swiss francs euros us dollars pounds sterling investments held strategic purposes classified noncurrent see note sharesthese consist primarily readily saleable equity securities finance report roche group notes roche group consolidated financial statements bonds debentures millions chf average effective average effective contracted maturity amount interest rate amount interest rate within one year one five years five years total bonds debentures money market instrumentsthese generally fixed interest rates ranging depending upon currency denominated contracted mature within one year december cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents restricted cash included within financial longterm assets see note current assets seenote accounts payable accounts payable millions chf trade accounts payable taxes payable accounts payable total accounts payable accrued current liabilities accrued current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities finance report roche group notes roche group consolidated financial statements derivative financial instruments appropriate circumstances group uses derivative financial instruments part risk management trading strategies discussed note derivative financial instruments carried fair value themethods used determining fair value described note derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts swaps interest rate derivatives swaps derivatives total derivative financial instruments hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropriate certain risks managed use derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described genentech hedged fixedterm debt instruments interest rate swaps december instruments designated qualify fair value hedges recorded balance sheet liability fair value million swiss francs liability million swiss francs genentech nonus dollar cash flows future royalty income development expenses expected next one five years hedge part transaction exposure genentech enters derivative financial instruments options forward contracts genentech equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure genentech enters derivative financial instruments zero cost collars forward contracts december instruments designated qualify hedge accounting recorded assets fair value million swiss francs liabilities fair value million swiss francs assets million swiss francs matters also described genentechs annual report quarterly sec filings movements fair value reserve designated cash flow hedges included note finance report roche group notes roche group consolidated financial statements provisions contingent liabilities provisions movements recognised liabilities millions chf environmental legal restructuring provisions provisions provisions total year ended december january major legal cases additional provisions created utilised year provisions additional provisions created unused amounts reversed utilised year unwinding discount currency translation effects december current portion noncurrent portion total provisions year ended december january major legal cases additional provisions created utilised year provisions additional provisions created unused amounts reversed utilised year unwinding discount currency translation effects december current portion noncurrent portion total provisions expected outflow resources within one year one two years two three years three years total provisions finance report roche group notes roche group consolidated financial statements environmental legal provisions provisions include million swiss francs million swiss francs environmental matters million swiss francs million swiss francs litigation including major legal cases vitamin case provisions environmental matters include various separate environmental issues number countries approximately half preexisting companies acquired group nature amounts timing outflows difficult predict group estimates approximately half amount provided may result cash outflows next five years significant provisions discounted legal provisions consist mainly major legal cases described note amounts timing uncertainties outflows discussed notes discount rates used remaining legal provisions account less balance consist number separate legal matters various group companies majority cash outflows expected occur within next one three years although dependent development various litigations provisions discounted time value money material matters restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group remaining amounts mostly respect obligations towards former employees arising pharmaceuticals division restructuring previous restructuring plans timings cash outflows reasonably certain global basis shown table significant provisions discounted provisions provisions consist mostly claims arising trade sales returns certain employee benefit obligations various provisions group companies fit categories timings cash outflows nature uncertain best estimates shown table significant provisions discounted contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable see also note respect major legal cases group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimate future commitments payments million swiss francs million swiss francs million swiss francs finance report roche group notes roche group consolidated financial statements noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities debt debt recognised liabilities millions chf debt instruments amounts due banks financial institutions genentech leasing obligations finance lease obligations borrowings total debt reported longterm debt shortterm debt total debt debt repayment terms millions chf within one year one two years two three years three four years four five years five years total debt lyons v zero coupon us dollar exchangeable notes see reflected due first year theholders notes request group purchase notes fair value debt instruments billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods pledges groups assets connection debt amounts due banks financial institutions amounts denominated various currencies notably canadian dollars swiss francs south african rand brazilian real average interest rate average interest rate balance primarily denominated euros repayment dates four years million swiss francs million swiss francs due within one year finance report roche group notes roche group consolidated financial statements debt instruments recognised liabilities effective interest rates debt instruments millions chf effective interest rate european medium term note programme bonds due october principal million euros bonds due august principal million pounds sterling bonds due october principal million us dollars swiss franc bonds rodeo due march principal billion swiss francs us dollar bonds chameleon due july principal million us dollars zero coupon us dollar exchangeable notes lyons v due july principal million us dollars genentech senior notes senior notes due july principal million us dollars senior notes due july principal billion us dollars senior notes due july principal million us dollars japanese yen convertible bonds issued chugai series chugai pharmaceutical unsecured convertible bonds due september principal amount million japanese yen billion japanese yen total debt instruments unamortised discount included carrying value debt instruments millions chf us dollar bonds sterling bonds zero coupon us dollar exchangeable notes total unamortised discount fair value option group applied fair value option three outstanding debt instruments group applying fair value hedge accounting past debt instruments european medium term note programme euro bonds chameleon us dollar bonds rodeo swiss franc bonds fair value option treatment based elimination accounting mismatch recognised hedging swaps reported fair value hedged bonds reported amortised cost difference carrying value principal amount debt instruments totals million swiss francs million swiss francs issues new debt instruments july genentech completed private placement billion us dollars aggregate principal amount senior notes placement consisted million us dollars senior notes due billion us dollars senior notes due million us dollars senior notes due senior notes contain certain restrictive covenants incurring property liens entering sale leaseback transactions finance report roche group notes roche group consolidated financial statements cash inflows issues new debt instruments millions chf genentech senior notes senior notes issued july senior notes issued july senior notes issued july total cash inflows new issues year repayments redemptions conversions debt instruments partial conversion lyons v us dollar exchangeable notesduring notes carrying value million us dollars million swiss francs converted million nonvoting equity securities notes called conversion represent number notes outstanding start year total million swiss francs recorded equity consists million swiss francs cash used purchase nonvoting equity securities used conversion less million swiss francs carrying value converted bonds related tax effects million swiss francs partial conversion series chugai pharmaceutical unsecured convertible bondsduring bonds face value billion japanese yen million swiss francs converted shares chugai groups percentage ownership chugai unaffected conversion group bonds convertible chugai shares mirror chugai outstanding third parties repayments redemptions conversions debt instruments redemption sumo japanese yen exchangeable bonds due date march group redeemed bonds original issue amount plus accrued original issue discount oid effective interest rate bonds cash outflow million swiss francs gain loss recorded redemption partial conversion repurchase lyons v us dollar exchangeable notes january group repurchased option bondholders total million us dollars nominal value notes total consideration million us dollars million swiss francs equal carrying value notes notes carrying value million swiss francs converted non voting equity securities notes repurchased called conversion represented number notes outstanding start year material impact financial statements partial conversion series chugai pharmaceutical unsecured convertible bondsduring bonds face value billion japanese yen million swiss francs converted shares chugai groups percentage ownership chugai unaffected conversion group bonds convertible chugai shares mirror chugai outstanding third parties cash outflows repayments redemptions debt instruments millions chf lyons v us dollar exchangeable notes sumo japanese yen exchangeable bonds total cash outflows repayments redemptions year terms outstanding convertible debt instruments lyons vthe notes exchangeable nonvoting equity securities nes american depositary shares ads exchange ratio nes exchange adss per usd principal amount maturity notes group purchase note cash option holder july july july purchase price per usd principal amount notes usd usd usd respectively addition notes redeemable option group whole part time july issue price plus accrued original issue discount oid ifthe notes outstanding december exchanged would require million nonvoting equity securities meet obligation finance report roche group notes roche group consolidated financial statements series chugai pharmaceutical unsecured convertible bonds bond jpy par value convertible shares chugai conversion option bondholder may made time september bonds redeemable maturity september issue price bonds outstanding december converted would require thousand chugai shares meet obligation groups percentage ownership chugai would affected conversion group bonds convertible chugai shares mirror chugai outstanding third parties equity attributable roche shareholders changes equity attributable roche shareholders millions chf share equity retained fair value hedging translation year ended december capital instruments earnings reserve reserve reserve total january restated availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations defined benefit plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity minority interests net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech share repurchases convertible debt instruments changes minority interests december finance report roche group notes roche group consolidated financial statements equity share instru retained fair value hedging translation year ended december capital ments earnings reserve reserve reserve total january availableforsale investments valuation gains losses taken equity transferred income statement sale impairment cash flow hedges gains losses taken equity transferred income statement transferred initial balance sheet carrying value hedged items exchange differences translation foreign operations defined benefit plans actuarial gains losses limit asset recognition income taxes items taken directly transferred equity minority interests net income recognised directly equity net income recognised income statement total recognised income expense dividends paid transactions equity instruments equity compensation plans genentech share repurchases convertible debt instruments changes minority interests december share capital december share capital roche holding ltd groups parent company consisted shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares thisis described note based information supplied group novartis international ltd basel affiliates participation issued shares finance report roche group notes roche group consolidated financial statements nonvoting equity securities genussscheine december nonvoting equity securities issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends february shareholders approved distribution dividend chf per share non voting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board proposed dividends business year swiss francs per share nonvoting equity security subject approval theannual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities december december millions millions nonvoting equity securities low exercise price options derivative instruments total equity instruments equity instruments recorded within equity original purchase cost details equity instruments held december shown table fair values disclosed information purposes equity instruments december supplementary information equivalent number nonvoting equity strike price market value securities millions maturity chf millions chf nonvoting equity securities na na low exercise price options jan nov derivative instruments feb feb total nonvoting equity securities low exercise price options mainly held potential conversion obligations may arise groups convertible debt instruments see note groups potential obligations employees roche option plan roche stocksettled stock appreciation rights see note covered call options exercisable time maturity group also holds aresidual number options purchased use groups previous option compensation scheme closed following conversion convertible debt instruments outstanding start year see note group reduced holdings equity instruments year net cash inflow transactions equity instruments million swiss francs net cash inflow million swiss francs group holds none shares finance report roche group notes roche group consolidated financial statements reserves fair value reserve fair value reserve represents cumulative net change fair value available forsale financial assets asset sold impaired otherwise disposed hedging reservethe hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reservethe translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs earnings per share nonvoting equity security basic earnings per share nonvoting equity security calculation basic earnings per share nonvoting equity security number shares non voting equity securities reduced weighted average number nonvoting equity securities held group period basic earnings per share nonvoting equity security continuing businesses group net income millions chf number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue used calculate basic earnings per share millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities potential dilutive effects arise convertible debt instruments employee stock option plans outstanding convertible debt instruments converted would lead reduction interest expense increase number shares may net dilutive effect earnings per share exercise outstanding vested employee stock options would dilutive effect exercise outstanding vested genentech employee stock options would dilutive effect net income genentech positive diluted earnings per share nonvoting equity security reflects potential impacts dilutive effects earnings per share figures finance report roche group notes roche group consolidated financial statements diluted earnings per share nonvoting equity security continuing businesses group net income millions chf elimination interest expense net tax convertible debt instruments dilutive millions chf increase minority share group net income net tax assuming outstanding genentech stock options exercised millions chf net income used calculate diluted earnings per share millions chf weighted average number shares nonvoting equity securities issue millions adjustment assumed conversion convertible debt instruments dilutive millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf minority interests changes equity attributable minority interests millions chf january restated net income recognised directly equity net income recognised income statement genentech chugai minority interests total net income recognised income statement total recognised income expense dividends paid minority shareholders equity compensation plans genentech share repurchases convertible debt instruments changes minority interests december genentech chugai minority interests total minority interests finance report roche group notes roche group consolidated financial statements related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares based information supplied shareholder group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri mscatherine oeri ms beatrice oeri ms maja oeri group holds shares preceding year represents issued shares figure include shares without pooled voting rights held outside group individual members group mr andr hoffmann dr andreas oeri members board directors roche holding ltd capacity receive annual remuneration swiss francs since february mr hoffmann vicechairman board received swiss francs capacity dr oeri chairman corporate governance sustainability committee receives swiss francs time expenses capacity transactions group individual members shareholder group subsidiaries associated companies listing major group subsidiaries associated companies included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associated companies key management personnel members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees remuneration members board directors chf compensation annual board committee remuneration members total executive director fb humer nonexecutive directors b gehrig r hnggi february hoffmann ji bell p brabeckletmathe ljr de vink w frey da julius oeri h teltschik b weder di mauro february total nonexecutive directors total remuneration board directors finance report roche group notes roche group consolidated financial statements remuneration prof gehrig includes serving independent lead director vicechairman board remuneration mr hnggi includes serving vicechairman board february remuneration mr hoffmann includes serving vicechairman board february remuneration nonexecutive members board directors totalled million swiss francs prof bell oneyear sabbatical leave university oxford since august spending year roche roche pay personal family expenses prof bell incurs relation stay switzerland including insurance costs expenses totalled swiss francs addition roche paid swiss francs retirement policy prof bell prof teltschik received honoraria including expenses amounting euros swiss francs serving boards several roche subsidiaries germany otherwise additional remuneration paid members board directors connection acquisition glycart july see note group paid mr hnggi swiss francs consideration shareholding glycart equivalent amounts paid shareholders glycart purchase shareholdings members corporate executive committee roche holding ltd receive remuneration indirect benefits participate certain equity compensation plans remuneration members executive committee chf expense annual salary bonus allowance total fb humer wm burns e hunziker ga keller jkc knowles schwan total annual salary amount dr humer includes swiss francs receives capacity member board directors described remuneration members executive committee totalled million swiss francs dr humer dr hunziker mr burns prof knowles received total us dollars swiss francs serving chugai board dr hunziker mr burns prof knowles also genentech board declined remuneration serving capacity mr h von prondzynski stepped executive committee december assisted transition successor resigned roche effective december paid salary swiss francs received bonus swiss francs respect expense allowance swiss francs otherwise additional remuneration paid current former members corporate executive committee group pays social insurance contributions respect remuneration pays contributions pension postemployment benefits plans members executive committee members executive committee may also participate roche connect employee stock purchase plan see note finance report roche group notes roche group consolidated financial statements indirect benefits employer contributions members executive committee chf pensions social insurance roche connect fb humer wm burns e hunziker ga keller jkc knowles schwan total owing amendments switzerlands federal occupational old age survivors disability pension act bvg contributions behalf dr humer limited swiss francs due existing contractual obligations dr humer additional provision swiss francs recognised group pension social insurance roche connect contributions paid group totalled million swiss francs addition group paid employer contributions swiss francs pensions swiss francs social insurance swiss francs roche connect respect mr von prondzynski roche longterm discussed note group implemented new global longterm incentive programme available certain directors management employees selected discretion group programme consists stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan rop members executive committee granted ssars rop awards ssars rop awards terms vesting conditions fair value awards disclosed note roche performance share plan disclosed note board approved threeyear cycle roche performance share plan operate threeyear cycle operate members executive committee targeted awards cycle awards cycle award result zero two nonvoting equity securities depending upon achievement performance targets allocated recipients february terms vesting conditions fair value awards disclosed note transactions members executive committee dr keller taken mortgage loan swiss francs pension fund f hoffmannla roche ltd interest rate pa dr keller repaid end group paid dr schwan swiss francs onetime relocation housing expenses pensions totalling swiss francs paid two former executive committee members postemployment benefit plans transactions group various postemployment defined benefit plans employees group described note finance report roche group notes roche group consolidated financial statements cash flow statement cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown cash flow statement operating cash flows also include income taxes paid activities including example taxes paid income bond conversion redemption cash generated operations millions chf net income add back nonoperating income expense associated companies financial income financing costs income taxes discontinued businesses operating profit depreciation property plant equipment amortisation intangible assets impairment intangible assets impairment property plant equipment major legal cases operating expenses defined benefit postemployment plans operating expenses equitysettled equity compensation plans adjustments cash generated continuing businesses operating cash flows generated discontinued businesses cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associated companies businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity finance report roche group notes roche group consolidated financial statements interest dividends paid millions chf interest paid dividends paid total significant noncash transactions additions property plant equipment million swiss francs recorded genentech leasing arrangements see note corresponding increase longterm debt significant noncash transactions subsequent events significant events balance sheet date subsidiaries associated companies listed companies share capital equity interest country company city mill switzerland roche holding ltd basel chf stock exchange swx zurich valor share valor genussscheine isin share ch isin genussscheinech market capitalisation chf mill basilea pharmaceutica ltd basel chf stock exchange swx bio zurich nasdaq biotech valor isin ch market capitalisation chf mill united states genentech inc south san francisco usd stock exchange new york incorporated delaware isin us market capitalisation usd mill japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy mill nonlisted companies share capital equity interest country company city mill argentina productos roche sa qumica e industrial buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur roche diagnostics graz gmbh graz eur belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur bermuda canadian pharmholding ltd hamilton usd corange international ltd hamilton usd corange ltd hamilton usd roche financial investments ltd hamilton usd roche financial services ltd hamilton usd roche interfinance ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl finance report roche group notes roche group consolidated financial statements share capital equity interest country company city mill bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa san jos usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark proteo pharma aps copenhagen dkk roche hvidovre dkk roche bio denmark copenhagen dkk roche diagnostics hvidovre dkk dominican productos roche dominicana sa santo domingo dop republic ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eek finland roche diagnostics oy espoo eur roche oy espoo eur france cenexi sas fontenaysousbois eur roche diagnostics sa meylan eur roche sas neuillysurseine eur germany disetronic medical systems gmbh sulzbach eur galenus mannheim gmbh mannheim eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics gmbh mannheim eur roche pharma ag grenzachwyhlen eur greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche scientific company india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius lit luxembourg pharminvest sa luxembourg eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex de mxico sa de cv mexico city mxn lakeside de mxico sa de cv mexico city mxn productos roche sa de cv mexico city mxn syntex sa de cv mexico city mxn morocco roche sa casablanca mad finance report roche group notes roche group consolidated financial statements share capital equity interest country company city mill netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics new zealand pty ltd auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan ltd karachi pkr panama productos roche interamericana sa panama city usd productos roche panam sa panama city pab syntex corporation panama city usd syntex puerto rico inc panama city usd technical development corp panama city chf peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc makati php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda lindaavelha eur romania roche romania srl bucharest ron russia roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk slovenia roche doo pharmaceutical company ljubljana sit south africa roche products proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland disetronic handels ag burgdorf chf disetronic holding ag burgdorf chf disetronic licensing ag burgdorf chf disetronic medical systems ag burgdorf chf f hoffmannla roche ltd basel chf glycart biotechnology ltd schlieren chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd zurichkloten chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd steinhausen chf roche finance ltd basel chf roche instrument center ltd rotkreuz chf roche capital market ltd basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try finance report roche group notes roche group consolidated financial statements share capital equity interest country company city mill united kingdom roche diagnostics ltd lewes gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp united states disetronic medical systems inc st paul usd hoffmannla roche inc nutley usd idaho technology inc salt lake city usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostics corporation indianapolis usd roche finance america inc wilmington usd roche finance usa inc wilmington usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche palo alto llc palo alto usd uruguay roche international ltd montevideo branch montevideo uyu sapac corporation ltd montevideo uyu venezuela productos roche sa caracas veb share capital less local currency units finance report report group auditors report group auditors annual general meeting roche holding ltd basel group auditors audited consolidated financial statements income statement balance sheet cashflow statement statement recognised income expense statement changes equity notes pages roche holding ltd year ended december consolidated financial statements responsibility board directors responsibility express opinion consolidated financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance swiss auditing standards international standards auditing isa require audit planned performed obtain reasonable assurance whether consolidated financial statements free material misstatement examined test basis evidence supporting amounts disclosures consolidated financial statements also assessed accounting principles used significant estimates made overall consolidated financial statement presentation believe audit provides reasonable basis opinion opinion consolidated financial statements give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law recommend consolidated financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris erik fj willems auditor charge basel february finance report multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable minority interests additions property plant equipment personnel number employees end year key ratios net income sales net income equity research development sales current ratio equity minority interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf c earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf c cash warrants addition dividend chf b information table stated reported changes accounting policies arising changes international financial reporting standards stock split applied retrospectively finance report roche group multiyear overview net income related key ratios shown special charges million swiss francs net tax incurred following corange acquisition include corange respect balance sheet data b assuming centenary warrants held final exercise date c dividend include special dividend relating spinoff fragrances flavours division dividend proposed board directors finance report roche group multiyear overview sales division millions chf pharmaceuticals diagnostics consumer health otc vitamins fine chemicals total sales geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics consumer health otc vitamins fine chemicals corporate total additions property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total finance report supplementary net income eps information groups basic diluted earnings per share information given note consolidated financial statements pages supplementary eps information given net income exceptional items also core net income additionally excludes amortisation intangible assets related impacts income taxes minority interests profit continuing businesses exceptional items core net income millions chf year ended december profit continuing businesses major legal cases income taxes profit continuing businesses exceptional items minority interests profit continuing businesses net income attributable roche shareholders continuing businesses exceptional items amortisation impairment intangible assets income taxes minority interest core net income eps continuing businesses exceptional items core eps eps continuing businesses exceptional items core eps year ended december net income attributable roche shareholders millions chf elimination interest expense net tax convertible debt instruments dilutive increase minority share net income net tax assuming outstanding genentech chugai stock options exercised net income used calculate diluted earnings per share per share information millions shares nonvoting equity securities weighted average number shares nonvoting equity securities issue adjustment assumed conversion convertible debt instruments dilutive adjustment assumed exercise equity compensation plans dilutive weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share earnings per share dilutedchf finance report roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased two roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july information tables restated change ratio adrs effective january finance report roche group roche securities number shares nonvoting equity securitiesa number shares nominal value chf number nonvoting equity securities genussscheine nominal value total data per share nonvoting equity security chf net income equity dividend c stock price shareb high low yearend stock price nonvoting equity security genussscheinb high low yearend market capitalisation millions chf yearend key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg ro sw rog vx rhhby us swx swiss exchange ro rog finance report roche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income income total income expenses financial expenses administration expenses expenses total expenses profit year taxes taxes net profit year finance report roche holding ltd basel financial statements balance sheet december millions chf noncurrent assets participations longterm loans group companies total noncurrent assets current assets shortterm loans group companies accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies unrealised foreign currency gains liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value finance report notes financial statements general financial statements roche holding ltd basel prepared accordance provisions swiss law valuation methods translation foreign currencies marketable securities reported lower cost market value assets including participations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred details specific items taxes tax charge includes corporate income capital taxes equity movement recognised amounts millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity non voting equity securities genussscheine part share capital confer voting rights however nonvoting equity security genussschein confer rights one shares participate available earnings remaining proceeds liquidation following repayment theshare capital guarantees within framework european medium term note emtn programme company issued guarantees favour group companies amounting million swiss francs previous year million swiss francs time preparing balance sheet risks arising contingent liabilities discernible finance report roche holding ltd basel notes financial statements convertibles options reference made notes roche group consolidated financial statements equity instruments reference made notes roche group consolidated financial statements pledged assets december assets pledged security companys commitments participations major participations listed note roche group consolidated financial statements important shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting february information available company previous year shares shareholder group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri mscatherine oeri ms beatrice oeri ms maja oeria previous year shares participation novartis international ltd basel including affiliates thereofb information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied novartis international ltd basel finance report appropriation available earnings proposals annual general meeting chf available earnings net profit year balance brought forward previous year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account finance report report statutory auditors report statutory auditors annual general meeting roche holding ltd basel statutory auditors audited accounting records financial statements income statement balance sheet notes pages roche holding ltd year ended december financial statements responsibility board directors responsibility express opinion financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance swiss auditing standards require audit planned performed obtain reasonable assurance whether financial statements free material misstatement examined test basis evidence supporting amounts disclosures financial statements also assessed accounting principles used significant estimates made overall financial statement presentation believe audit provides reasonable basis opinion opinion accounting records financial statements proposed appropriation available earnings comply swiss law companys articles incorporation recommend financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris erik fj willems auditor charge basel february finance report published cautionary statement regarding forward fhoffmannla roche ltd looking statements baselswitzerland annual report contains certain forwardlook tel ing statements forwardlooking statements fax may identified words believes expects anticipates projects intends media office seeks estimates future similar expressions corporate communications discussion among things strategy baselswitzerland goals plans intentions various factors may tel cause actual results differ materially future fax reflected forwardlooking statements contained annual report among others investor relations pricing product initiatives competitors baselswitzerland legislative regulatory developments tel economic conditions delay inability fax obtaining regulatory approvals bringing prod ucts market fluctuations currency world wide web exchange rates general financial market condi httpwwwrochecom tions uncertainties discovery develop ment marketing new products new uses order publications existing products including without limitation tel negative results ofclinical trials research projects fax unexpected side effects pipeline marketed emailbaselwebmasterrochecom products increased government pricing pres sures interruptions production loss orinability obtain adequate protection intel lectual property rights litigation loss key executives employeesand adverse publicity news coverage statement regarding earnings per share growth profit forecast inter preted mean roches earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share ofroche next annual general meeting march trademarks mentioned enjoy legal protection roche annual report published german english roche annual report issued f hoffmannla roche ltd basel corporate communications finance report